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Protein arginine methylation has become of interest in recent years for its 
involvement in diverse cellular processes. This modification is catalysed by protein 
arginine methyltransferases (PRMTs). PRMT1 is the predominant methyltransferase 
in eukaryotes, performing 85% of all cellular arginine methylation. There are 7 known 
PRMT1 splice-variants which vary in cellular localisation and activity. Several 
physiological processes, including gene expression and cellular signalling, have 
been shown to involve PRMT1. Furthermore, PRMT1 is upregulated in several 
cancers and its direct involvement in progression of leukaemia and ERα-driven 
breast cancers is evident. Information regarding PRMT1 regulation is lacking. The 
Davies laboratory recently discovered potential interactions between PRMT1v1 and 
the deubiquitylases USP11 and USP7. However, it was unknown if these 
interactions were direct or indirect. To address this, we generated recombinant 
proteins of His-SUMO-PRMT1v2, GST-USP11 and GST-USP7 for use within pull-
down protein-interaction assays. Both GST-USP11 and GST-USP7 were capable of 
direct interaction with His-SUMO-PRMT1v2. These interactions were not seen under 
non-physiological NaCl levels, suggesting that such events could occur in vivo. It is 
unconfirmed if such interactions are enzyme-substrate events or whether they 
regulate protein activity through direct binding. Once this is elucidated, intervention 
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1.1 The structure and regulation of PRMT1 
PRMT1 is the major type I protein arginine methyltransferase in eukaryotes (1, 2); it 
conducts asymmetric dimethylation and shares conserved structural features of the 
other 8 enzymatically active PRMTs. Arginine methylation and PRMT family 
members are summarised in Figures 1 and 2. PRMT1 is present throughout 
embryonic and adult tissues and is thought to catalyse 85% of total arginine 
methylation, based on PRMT1 immunodepletion in rat liver preparations (1). The 
embryonic lethality of PRMT1 knockout mice suggests it has necessary functions in 
embryonic development (3). Furthermore, conditional knockout of PRMT1 in mouse 
embryonic fibroblasts (MEFs) results in the dysregulation of the cell cycle and 
genomic instability (2). These studies display the importance of PRMT1 in the 
regulation of normal cellular functioning. PRMT1 generally methylates arginines 
within glycine-rich sequences, the RGG/RG motifs, which allows potential substrates 
to be identified to some degree of confidence (4). However, there are exceptions to 
this observation; RING domain activator AP-1 coactivator-1 (RACO) is methylated by 
PRMT1 but does not possess this motif (5). Additionally, other residues, distal to the 
methylated arginine are thought to contribute to substrate recognition and direct 
methylation (6, 7).  
The ubiquitous nature of PRMT1 suggests it must possess a complex regulatory 
system, although the details of such mechanisms are lacking. Studies have shown 
that its activity is controlled through the formation of complexes with regulatory 
proteins. PRMT1 interacts individually with B-cell translocation genes 1 and 2 (BTG1 
and BTG2) (8). The addition of either protein was shown to increase the activity of 
exogenous PRMT1, as well as to activate latent endogenous PRMT1 in quiescent rat 
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fibroblasts, suggesting that each can act as positive regulators (9). Following this, 
another binding partner of BTG1, CCR4-associated factor 1 (hCAF1), was also 
found to influence the activity of nuclear PRMT1 (10). Using siRNA, it was shown 
that hCAF1 inhibits the methylation of Sam68 and histone H4R3 by PRMT1. PRMT1 
activity is also regulated through PTM, as it has recently been shown to be 
phosphorylated at Tyr291, juxtaposed to the THW domain, resulting in an 
impairment of substrate binding and methylation (11).  Further research has shown 
that PRMT1 methylation may also be regulated through crosstalk with other PTMs 
(12). For example, asymmetric methylation by PRMT1 of H4R3 promotes the 
acetylation of lysine 5 (H4K5ac). This leads to chromatin relaxation which promotes 
transcriptional activation (12, 13). Conversely, K5 acetylation promotes symmetric 
methylation of H4R3 by PRMT5, causing transcriptional repression (12). Thus, H4K5 
acetylation acts as a mediator, providing a negative feedback mechanism between 
two PRMTs with distinct methyltransferase activity. As PRMT1 is involved in many 
important, interlinking processes, there are likely to be other mechanisms which 













































Figure 1 Process of Arginine Methylation by Protein arginine methyltransferases (PRMTs). 
All PRMTs initially conduct monomethylation at a single guanadino group of an arginine residue. 
Following this, a second methyl group can be added to same guanadino group by type 1 PRMTs, 
forming asymmetric dimethyl-arginine (ADMA). Alternatively, this second methyl group may be 
added to the next guanadino group by type II PRMTs, giving rise to symmetric dimethyl-arginine 
(SDMA). Each step requires S-Adenosylmethionine (AdoMet) as a methyl group donor, 
consequently yielding S-adenosyl-L-homocysteine (AdoHcy). Diagram from Pahlich et al, 
BiochimBiophys Acta (4).  
Figure 2: Members of the PRMT family with Methyltransferase activity: Type 1 enzymes give rise to 
asymmetric dimethyl-arginine (ADMA), whereas type 2 members yield symmetric dimethyl-arginine (SDMA). 
Each share a common methyltransferase domain, as well as a conserved THW loop, which defines them as a 
members of the PRMT family. PRMT7 contains two methyltransferase domains. Other members contain N-
terminal alterations which affect their localisation and substrate specificity. For example, PRMT8 is largely 
associated at the plasma membrane due the myristoyl group, and the SH3 domain of PRMT2 allows for 
interactions with PRMT8. 
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1.1.1 PRMT1 is alternatively Spliced 
The prmt1 gene comprises 12 exons, the first 5 of which undergo alternate splicing, 
giving rise to 7 known isoforms with distinct N-terminal protein sequences (9, 14). 
RT-PCR analysis of human tissues shows that each isoform possesses distinct 
expression profiles (Figure 3) (14).  For example, isoform 4 (PRMT1v4) is uniquely 
expressed in heart tissue, whereas PRMT1v5 is predominantly expressed in the 
pancreas. The activity of such organ-exclusive isoforms may be tailored to the 
specific requirements of each tissue. The only two isoforms expressed in multiple 
tissues are PRMT1v1 and PRMT1v2 (14). These differ through the inclusion of exon 
2 in PRMT1v2 (Figure 3). Amino acid sequence analysis and mutagenesis studies 
have demonstrated that exon 2 contains a CARM1-dependent nuclear export signal 
(15VATLANGMSL24), thereby explaining the observation that PRMT1v2 is generally 
cytoplasmic, whereas PRMT1v1 is nuclear (14). As such, the subcellular localisation 
of these isoforms dictates their individual substrate specificity and activity (15). The 
evidence for this is discussed in section 1.4. The structural differences and 
distribution of individual isoforms is likely to contribute to the widespread, diverse 










1.2 PRMT1 regulates diverse cellular processes  
1.2.1 Histone Methylation and gene expression 
 
PRMT1 is a well-characterised coactivator of transcription via the methylation of 
H4R3.  One mechanism by which increased gene activation occurs is through the 
recruitment and activation of the histone acetyltransferase p300, subsequently 
leading to H4K5 acetylation (12, 16). Acetylation-mediated chromatin relaxation 
allows for the recruitment of transcription factors and other co-activators. PRMT1 has 
been shown to interact with numerous nuclear receptors and is an important 
regulator of oestrogen receptor alpha (ERα) (16-18). This steroid receptor undergoes 
a conformational change upon binding oestradiol, which leads to the activation of 
exonuclear signal transduction, namely the phosphatidylinositol-3-kinase (PI3K) 
pathway, or activation of genes under the control of oestrogen response elements 
(ERE) (19, 20) . Both events result in breast epithelial cell proliferation. PRMT1 
upregulates the transcriptional activity of ERα in response to oestradiol in breast 
cancer cells, through the recruitment of p300 to the pS2 promoter (17). This 



















Figure 3: PRMT1 undergoes  N-terminal alternate splicing  yielding 7 different isoforms: A 
Schematic representing the N-terminal alterations between exons 1 and 5 of PRMT1 splice variants.  
Amino acid and DNA sequence are shown for exon 2 included for PRMT1v2. Nuclear export sequence 
is highlighted in blue. Taken from Baldwin et al, Cell Cycle, 2012 (23). B RT-PCR analysis of expression 
for PRMT1 splice variants in human tissues. Actin represents cDNA loading control. Taken from Goulet 






Additionally, many studies have observed PRMT1-mediated transcriptional activation 
through interactions with co-activation proteins. For example, it was also found that 
PRMT1 methylates the transcriptional coactivator peroxisome proliferator-activated 
receptor γ coactivator-1α (PGC-1α) (21). PGC-1α associates with nuclear receptors 
and augments the expression of genes under its control. It was found that 
methylation of PGC-1α by PRMT1 leads to its increased activation and potentiating 
the activity of ERα, glucocorticoid receptor and thyroid receptor (21). This represents 
another level at which PRMT1 contributes to ERα-regulation and displays its 
necessity for nuclear receptor-mediated gene expression.  More recently, PRMT1 
was shown to form a regulatory complex with the AP-1/c-Jun transcription factor and 
a co-regulator protein RACO-1 (5). In this instance, RACO-1 is methylated twice by 
PRMT1 at R98 and R109. This leads to increased protein stability by the inhibition of 
autoubiquitylation and a conformational change, allowing RACO-1 to dimerise and 
then interact with c-Jun. Subsequently, the AP-1 transcriptional complex is activated, 
allowing for gene expression changes and cellular proliferation. Taken together, 
these studies show how PRMT1 is capable of widespread manipulation of gene 








1.2.2 Signalling and Survival  
More recently, evidence has implicated PRMT1 in processes of cell signalling and 
survival. As well as acting as a coactivator of ERα mediated transcription, PRMT1 
has also been implicated in oestrogen-dependent exonuclear signal transduction. 
Romancer et al, 2008 showed that ERα is methylated in the cytoplasm by PRMT1, 
resulting in the formation of a complex containing kinase Src and the p85 subunit of 
PI3K (18) . This leads to the activation of mitogen-activated protein kinase (MAPK) 
and Akt signalling and cellular proliferation. Methylation by PRMT1 was shown to be 
necessary for the formation of this complex. Therefore, it is evident that PRMT1 
mediation of ERα is complex, regulating both gene transcription and exonuclear 
signalling.  
 
The activity of PRMT1 plays an important role in Wnt signalling through interactions 
with β-catenin (22). This is an important signalling pathway involved in cell fate 
determination, cell proliferation and development. Under non-signalling conditions, β-
catenin is phosphorylated by glycogen synthase kinase 3β (GSK3β) and casein 
kinase 1 (CK1) (23). This permits its ubiquitylation by β-TrCP, targeting the protein 
for proteasomal degradation. This phosphorylation is made possible through 
interactions with scaffolding proteins APC and Axin. Wnt-mediated activation of the  
Frizzled receptor results in the ‘destruction complex’ of Axin, APC and GSK3β 
becoming localised to the cytoplasmic tail of lipoprotein receptor-related protein 5,6 
(LRP-5,6), enabling its phosphorylation to occur (23). Axin subsequently binds these 
phosphorylation sites and is sequestered at the cell membrane. This allows for 
cytoplasmic accumulation and subsequent nuclear localisation of β-catenin, leading 
to TCF-LEF-dependent transcriptional activation (23, 24). Cha et al showed that Axin 
interacts with PRMT1 and is methylated at R378 (22). This methylation event 
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increased the stability of Axin and promoted interactions with GSK3β. Hence, a 
reduction in PRMT1 by siRNA-mediated knockdown resulted in increased stability of 
β-catenin (22). Taken together, this suggested that PRMT1 acts a negative regulator 
of the Wnt signalling pathway, through stabilisation of Axin and the destruction 
complex.  
1.3 PRMT1 and Cancer 
PRMT1 is involved in several processes, including survival signalling, DNA repair 
and gene activation, which are commonly deregulated in cancer (25). This suggests 
a potential role of PRMT1 in tumourigenesis. Studies have shown elevated PRMT1 
expression in leukaemia, as well as in breast, colorectal, prostate, bladder and lung 
cancers (18, 26-30). Importantly, siRNA knockdowns of PRMT1 in cancer cell lines, 
including breast, bladder, lung and leukaemia, were shown to reduce cancer cell 
proliferation and viability (15, 29-31). Recent studies have shown a direct 
involvement of this enzyme in malignant progression. Cheung et al demonstrated 
that PRMT1 was required for the transforming properties of the Multiple Lineage 
Leukaemia (MLL) fusion protein (31). Using chimeras of MLL fused with the PRMT1 
interacting protein, SAM68, as well as PRMT1 directly, they were able to recapitulate 
the immortalisation conferred by the founding member of MLL-fusion proteins, MLL-
EEN. Furthermore, PRMT1 siRINA-knockdowns abolished this activity, suggesting 
the necessary requirement of PRMT1 in tumourigenesis. 
ERα methylation has also been implicated in breast cancer development (18). The 
activation of stimulatory signalling pathways by ERα is heavily implicated in breast 
cancer tumourigenesis, with approximately 70% of all breast tumours being positive 
for this receptor. Immunohistochemical analysis of breast tumours has shown that 
50% show much higher levels of methylated ERα, compared to normal breast 
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tissues (18). Furthermore, increased levels of PRMT1 in breast cancers correlate to 
lower disease free survival and a poorer prognosis (32). In this case, the status of 
PRMT1 expression could be used as a diagnostic factor. The evidence presented 
indicates PRMT1 as a tumourigenic protein, although the processes through which it 
promotes cancer progression are poorly understood.  
1.4 PRMT1v1 and PRMT1v2 display differential roles in 
pathogenesis 
PRMT1v1 and PRMT1v2 have clearly defined roles in breast cancer (14, 15). RNAi-
mediated silencing of PRMT1v2 expression caused a decrease in breast cancer cell 
viability and induced apoptosis in MCF7 breast cancer cell lines (15). Concurrent 
with this, overexpression of PRMT1v2 in the same cell line resulted in a more motile 
and invasive phenotype, that did not form tight colonies, suggesting a loss of cell-cell 
adhesions. Accordingly, cytoplasmic β-catenin levels were reduced. As well as being 
a major component of Wnt signalling, β-catenin also regulates cell adhesion through 
interactions with cadherins (23). In contrast, PRMT1v1 overexpression did not 
promote an invasive phenotype. All of these observations are in agreement with 
previous evidence; PRMT1 was thought to be a negative regulator of Wnt signalling 
through interactions with Axin (22). As Axin is a cytoplasmic protein, PRMT1v2 is 
likely the major regulator of this process. Overall, this study suggests that PRMT1v2 
may have a more profound effect on breast cancer development than PRMT1v1.  
It is notable, however, that PRMT1v1 overexpression, whilst not affecting invasion, 
increases the motility of breast cancer cells (15).  As this was not associated with a 
depletion of β-catenin, it seems that PRMT1v1 is also tumourigenic, but acts through 
different mechanisms than PRMT1v2, perhaps due to their distinct cellular 
compartmentalisation. Consistent with this, a separate study found that lower 
17 
 
expression of PRMT1v1 was associated with a higher disease-free survival, where 
as PRMT1v2 expression did not correlate with disease progression. Taken together 
the results of such studies display a direct involvement of PRMT1 in cancer 
progression and that different isoforms contribute to tumourigenesis through 
separate mechanisms.  
1.5 Previous work in the Davies lab shows that PRMT1 
interacts with USP7 and USP11 
Correlative and functional data linking PRMT1 to cancer is strong. However a 
mechanistic understanding into how aberrant arginine-methylation promotes 
tumourigenesis is lacking. To address this, the Davies lab uses affinity purification 
strategies, coupled with mass spectrometry analysis to identify novel binding 
partners of PRMT1, in the context of cancer. In particular, the lab employs Tandem 
Affinity Purification (TAP) assays for investigating such protein interactions. This 
stringent technique employs two consecutive rounds of affinity-purification, using a 
recombinant protein featuring a “bait” protein of interest attached to the “TAP-tag” 
(Figure 4A) (33). The tag used by the Davies lab comprises a Staphylococcus 
aureus protein A domain, which binds IgG sepharose beads for an initial purification 
step. A tobacco etch virus (TEV) protease cleavage site enables cleavage of the 
protein complexes isolated with the composite TAP-tag from IgG sepharose. The 
second tag, calmodulin binding protein (CBP), binds to calmodulin beads, enabling a 
second purification step. Stable human embryonic kidney 293T (HEK293T) cell lines 
were created expressing a tetracycline inducible TAP-vector. A methyltransferase-
dead (MD) PRMT1v1 was used as bait in order to facilitate the trapping of PRMT1v1 
substrates. Cells were stimulated with tetracycline for 48 hours, enabling expression 
of the TAP-tag PRMT1v1 MD protein before being harvested and lysed. Cell lysates 
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from induced and un-induced cells were subjected to affinity purification assays, 
protein complexes were resolved by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and the identity of specific PRMT1v1 interacting 
proteins were determined by mass spectrometry (MS) (Figure 4B). The analysis 
identified heterogeneous nuclear ribonucleoprotein U (hnRNP-U) and Ubiquitin-
specific protease 11 (USP11) as interacting proteins for PRMT1. The hnRNP family 
of proteins are involved in correct processing of mRNA. These proteins account for 
65% of asymmetrically methylated proteins in the nucleus and have already been 
identified as substrates of PRMT1(34). As such, hnRNP-U acts as a positive control, 
showing that this assay can pull-out both novel and known PRMT1 interactors.  
USP11 however had not previously been identified as a substrate or interacting 
protein of PRMT1.  
Upon further review of the literature, it was found that USP11 is known to directly 
interact with the related protein USP7 (or HAUSP) (Figure 4C) (35, 36). To validate 
the MS findings, ectopic immunoprecipitation assays were conducted using myc-
tagged PRMT1 and haemagglutinin (HA)-tagged USP11 or USP7.  PRMT1 
immunoprecipitated both USP7 and USP11 suggesting that PRMT1 interacts with 























































Figure 4: Previous work in the lab showing potential interactions between PRMT1, USP7 and USP11: A 
Schematic of TAP-tagged recombinant PRMT1v1. TEV; Tobacco etch virus cleavage site; CBP; Calmodulin binding 
protein. B Western blot and mass spectrometry data of PRMT1 TAP-tag assay. HEK293T cells were transfected for 
stable expression of tetracycline-inducible TAP-PRMT1v1 construct. The lysates from tetracycline treated and 
untreated cells were subjected to the TAP-tag purification assay. Extracted proteins were resolved through SDS-
PAGE and western blotting. Protein bands exclusive to induced cells were cut out and analysed by mass 
spectrometry. Table represents the number of peptides used which match the identified protein and the percentage 
coverage of their protein sequences. B String diagram representing known interactions involving USP11. 
Source:www.string-db.org. C myc-PRMT1 Immunoprecipitation (IP) assay; HEK293T cells were transfected with 
myc-tagged PRMT1 together with haemagglutinin-tagged USP11 or USP7. Lysates were then incubated with anti-
myc monocloncal antibody-conjugated sepharose beads. IPs were then resolved using sodium dodecyl sulphate-






1.6 USP7 and USP11 are important Deubiquitylases (DUBs) 
Deubiquitylases (DUBs) catalyse the removal of ubiquitin chains from substrates. 
The removal of K48-linked chains generally leads to the stabilisation and 
accumulation of their substrates (37).  Five families of DUB exist, each of which are 
separated based on their specific enzymatic activity. The ubiquitin-specific proteases 
(USPs) family of DUBs share a common catalytic process; a conserved triad of 
aspartate, histidine and cysteine in the catalytic domain carry out a nucleophilic 
attack on isopeptide bonds joining adjacent ubiquitin molecule (Figure 5) (37). USPs 
are the largest DUB family, with each member possessing accessory domains that 
dictate their activity and available substrates. However, each member does not 
discriminate between different ubiquitin chain linkages, with the exceptions of USPL1 
and USP18, which removes Small Ubiquitin-like Modifier (SUMO) and ISG15 (38, 
39). As such, the outcome of their activities is dictated by their substrate specificity. 
Many USPs have known roles in DNA damage repair and the aberrant expression of 
























Figure 5: Schematic of ubiquitin-specific protease catalytic activity. Catalytic triad composed of 
aspartate, histidine and cysteine conducts a nucleophilic attack against isopeptide bonds linking two 
ubiquitin molecules. S1 and S1’ represent binding sites for both proximal and distal ubiquitins. Taken 
from Clague et al, 2013 (44) 
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1.6.1 The functions of USP11 
USP11 is predominantly found in the brain and varies in cellular localisation 
depending on the current state of cell division (40, 41). Studies have shown it to be a 
key mediator of DSB repair (42, 43). siRNA knockdown of USP11 elicited a greater 
rate of spontaneous DNA damage and malfunctioning homologous repair and a 
reduced recruitment of RAD50 and 53BP1 to foci of DSBs (43). Furthermore, it was 
found that USP11 also interacts with BRCA2, a necessary regulator of DNA repair 
(42). USP11 has also been heavily implicated in inflammatory signalling (44). 
Together with related proteins, it has also been show to function as part of tumour 
growth factor-beta signalling (TGFβ)(45). Upon TGFβ receptor activation, the 
expression of SMAD7 is increased. SMAD7 targets TGFβ receptors for ubiquitylation 
and proteasomal degradation. USP11 has been shown to directly interact with 
SMAD7, leading to the deubiquitylation and stabilisation of ALK5, a type 1 TGFβ 
receptor (45). In line with this, USP11 inhibition caused a reduction in TGFβ 
signalling and epithelial-mesenchymal transition (EMT). Since TGFβ signalling and 
EMT are important for malignant progression, these results imply that USP11 may 
function as an oncogene.  
1.6.2 The functions of USP7/HAUSP 
USP7 has gained a large amount of interest as a critical regulator of development; 
USP7 knockout mice are embryonic lethal, due to a deregulation of p53 (46). This 
well-known tumour suppressor is under tight control by the E3-ligase, MDM2. In 
response to DNA damage, MDM2 is destabilised, which frees p53 from proteasomal 
degradation. USP7 binds and destabilises MDM2, but also deubiquitylates p53 (46, 
47). Both processes lead to p53 stabilisation and promote its activity. Interestingly, 
although reduced levels of USP7 lead to p53 destabilisation, its complete loss results 
in further stabilisation. This is likely in part due to the effect of the interaction 
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between USP7 and MDMX; a negative transcriptional regulator of p53, which is also 
stabilised by USP7 (47). Thus, USP7 is a vital regulator of p53, through multiple 
protein interactions.  
1.6.3 USP11 and USP7 interact and conduct shared cellular processes 
Although USP11 and USP7 have their own distinct set of interacting proteins, both of 
these enzymes are predominantly found in the nucleus and are capable of 
interacting with each other (36). Moreover, a recent study showed how USP11 and 
USP7 interact, subsequently regulating the activity of Polycomb group (PcG) 
proteins MEL18 and BMI1 (35). These proteins are responsible for the repression of 
the INK4a/ARF locus, which encodes tumour suppressors p16INK4a and p14ARF. It 
was found that both USP11 and USP7 alter the ubiquitylation status of PcG proteins. 
Deubiquitylation results in a larger association at chromatin and further repression of 
the INK4a/ARF locus. Thus it is evident that, despite each protein possesing diverse 
substrate repertoires, both USPs are capable of cooperating to induce a specific 
phenotype.  
1.7 Project Aims – Does PRMT1 directly interact with USP7 
and USP11?  
The Davies lab identified USP11, but not USP7, as a substrate of PRMT1 using 
TAP-tag affinity purification. However, in cells, it was shown that both USPs were 
capable of interacting with PRMT1. It is currently unknown as to whether the 
interactions between PRMT1 and these related proteins are direct or indirect. TAP-
tag experiments suggest USP7 may indirectly interact with PRMT1 through USP11, 
whereas immunoprecipitation assays imply that a complex exists. In order to 
discover the nature of this interaction, plasmids expressing recombinant tagged 
constructs of PRMT1, USP11 and USP7 will be cloned into bacteria. Recombinant 
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protein will then be purified and used for pull-down assays in order to determine if 




















2 MATERIALS AND METHODS 
2.1 Antibodies 
 
Antibody Source Purpose 
Rabbit Anti-PRMT1 
Cell Signalling Technology 
(F339) 





(Horseraddish peroxidise)  
Dako (P0217) 
Western Blot Secondary 
(1:5000) 
  
2.2 Bacterial Strains 
 





PRMT1v2 and extracting 
DNA 
Rosetta™ BL21 DE3 
Competent Cells 
EMD Millipore (70954) 
Expression and purification 
of His-SUMO-PRMT1v2 





Table 1: Details of the antibodies used throughout the investigation 




Plasmid Source Components Purpose 
GFP-PRMT1v2 











PRMT1v2; Donor  
pET28-His-SUMO 








PRMT1v2; Vector  
pGM-GST-USP11 











Kind gift from 
Goedele Maertens, 
Imperial College, 









Reagent Purpose Components 
TAE Buffer (Tris-acetate-
EDTA) 
Component of agarose gel 
and agarose 
electrophoresis 
40mM Tris base 
5.71% (v/v) Glacial Acetic Acid 
1mM Ethylenediaminetetraacetic 





Separation of DNA through 
electrophoresis 
1% (w/v) Agarose (Sigma) 
0.01% (v/v) Ethidium Bromide 
100ml TAE  
Agar plates with 
kanamycin 
Growth of transformed 
bacteria 
2% (w/v) LB broth (Sigma™; 
L3022) 
1.4% (w/v) LB Agar (Sigma™ 
L2897) 
50µg/ml kanamycin 
Agar plates with ampicillin 
Growth of transformed 
bacteria 
2% (w/v) LB broth (Sigma™; 
L3022) 
1.4% (w/v) LB Agar (Sigma™ 
L2897) 
100µg/ml ampicillin 




5% (v/v) Glycerol 
10mM β-Mercaptoethanol 
50mM sodium diphydrphosphate 
(NaH2PO4) 











5% (v/v) Glycerol 
10mM β-Mercaptoethanol 
50mM sodium diphydrophosphate 
(NaH2PO4) 




Elution of His-SUMO 
PRMT1v2 
300mM NaCl 
5% (v/v) Glycerol 
10mM β-Mercaptoethanol 
50mM sodium diphydrophosphate 
(NaH2PO4) 





Purification of GST-USP11 
and GST-USP7 
50mM Tris-HCL pH 7.4 
2mM EDTA 











Purification of GST-USP11 
and GST-USP7 






25mM Tris Base 
50mM Glycine 
0.01% (w/v) sodium dodecyl 
sulphate (SDS) 
Fixing Solution Coomassie Staining 
10% (v/v) Glacial Acetic Acid 
50% (v/v) MeOH 
Coomassie Blue Stain Coomassie Staining 
10% (v/v) Glacial Acetic Acid 
45% (v/v) MeOH 
3mM Coomassie Brilliant Blue  
Destaining Solution Coomassie Staining 
10% (v/v) Glacial Acetic Acid 
45% (v/v) MeOH 
5X Laemmli Sample 
Buffer 
SDS-PAGE 
2.5% (w/v) Bromophenol blue 
2.5M DTT 
25% SDS 
2.5M Tris-HCL pH6.8 
Transfer Buffer (pH 8.3) Western Blotting 
25mM Tris 
192mM Glycine 
0.1% (w/v) SDS 
20% (v/v) MeOH 
Tris Buffered Saline (TBS) Western Blotting 20mM Tris Base 
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pH 7.6 137mM NaCl 
TBS Tween (TBST) Western Blotting 
TBS 




Name Purpose Sequence 
P1V2F Forward primer: PCR 
amplification of PRMT1v2 
5’- ccaggatccgcggcagccgaggccgcga-3’ 
P1V2R Reverse Primer: PCR 




2. 5.2 PCR Amplification of PRMTv2 
PRMT1v2 was amplified via polymerase chain reaction (PCR) using the procedures 
and reagents stated below. Forward primer contains BamH1 recognition site 
(GGATCC). Reverse primer contains Not1 recognition site (GCGGCCGC) and 2 
stop codons (TCA). Both primers comprise an excess 5’ codon providing a larger 
binding site for restriction enzymes. Accuzyme (Bioline; BIO-21051) DNA 
polymerase was used as it conducts proofreading. Dimethyl sulfoxide (DMSO) was 




 Table 5: Details of  primers used for cloning within this investigation 


























Scott 1 Primer  500nM 
Scott 2 Primer 500nM 











 Initialization step - 95°C –  3 
min 
 Denaturation step – 95°C 30 
sec 
 Annealing step - 60°C – 45 sec 
 Extension step – 72°C – 1.4 
min 
  Final extension - 72°C – 10 
min 
  Hold - 4°C 
 
35 Cycles 
Figure 6: Details of polymerase chain reaction (PCR) procedures used for 
cloning within this investigation: A Components of PCR mixture. B Details of 




2.5.3 Cloning of PRMT1v2 into pET28-His-SUMO 
PCR products were purified using agarose gel electrophoresis. Samples were run at 
80V for 1 hour on a 1% agarose gel in TAE. Bands were excised and DNA was 
extracted using an E.Z.N.A Poly-Gel DNA Extraction Kit (OMEGA Biotek D2561) as 
per the manufacturer’s instructions. 
PRMT1v2 PCR products and 20 µl pET28-His-SUMO were digested overnight with 
both BamH1-HF (New England Biolabs [NEB]; R3136) and Not1-HF (NEB; N3189) 
overnight or for 2 hours at 37°C.  Additional buffer and reagent requirements for 
each enzyme were fulfilled as per the manufacturers guidelines.  pET28-His-SUMO 
then was treated with 10U calf-intestinal alkaline phosphatase (CIP; NEB M0290) for 
20 min at 37°C to remove 5’ phosphate groups and prevent re-ligation of the vector. 
DNA was then extracted from the enzymatic reaction using an E.Z.N.A Poly-Gel 
DNA Extraction Kit. The concentrations of both vector and insert were elucidated by 
NanoDrop. 
Ligation was then conducted using a vector: insert ratio of 1:3. DNA was incubated 
with 40U T4 DNA Ligase (NEB M0202S) in 1X T4 ligase buffer (NEB; B0202S) for 3 
hours at room temperature (RT). A separate ligation containing pre-digested pET28-
His-SUMO alone was conducted as a control for ligation and enzymatic digest 
efficiency following bacterial transformation. Ligated pET28-His-SUMO-PRMT1v2 or 
pET28-His-SUMO control was used to transform DH5α competent bacteria. 10µl of 
ligation reaction was added to 50µl bacteria on ice. After 20min, bacteria were heat-
shocked at 42°C for 30sec and then allowed to rest on ice for 2min. Bacteria were 
then incubated for 1 hour at 37°C, 200rpm with 9-times the original volume (450µl) of 
super optimal broth with catabolite repression (SOC) medium (Sigma; S1797). 
Cultures were then plated on agar plates containing kanamycin. In order to identify 
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positive clones, bacterial were picked and grown in 4ml LB broth with 50µg/ml 
kanamycin overnight at 37°C, 200rpm. DNA was extracted from cultures using a 
plasmid Minikit (OMEGA Biotek D6942) according to manufacturer’s instructions. 
Plasmid preps were digested with Bam1-HF and Not1-HF and then separated by 
agarose electrophoresis as described earlier. The presence of a 1Kb insert indicated 
if bacteria were expressing the PRMT1v2 open-reading frame.  
2.6 Purification of His-SUMO PRMT1v2 Protein from Rosetta 
Bacteria using Ni+ NTA Agarose  
To obtain recombinant His-SUMO PRMT1v2, pET28-His-SUMO-PRMT1v2 was 
used to transform Rosetta BL21 DE3 bacteria according the suppliers 
recommendations. Single colonies were picked and used to inoculate 50ml of LB 
broth. This starter culture was incubated overnight at 37°C, 200rpm. 10ml of this 
culture was used to inoculate 4x500ml LB broth, giving a 2L total. Each culture was 
propagated at 37°C, 200rpm to an optical density (OD) of 0.4-0.6. Plasmid 
expression was then stimulated in each culture with the additional of 400µM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG). Cultures were grown for a further 4 
hours under the same conditions, before centrifugation at 4000g, 10min at 4°C. 
Pellets were resuspended in Ni+ NTA lysis buffer and sonicated twice on ice for 10s 
at 40% amplitude. Bacterial lysates were then incubated on ice with 1mg/ml 
lysozyme for 10mins and then centrifuged at 20,000g for 20min at 4°C. A 50µl 
sample of supernatent was maintained for later analysis of all soluble proteins; 
soluble fraction. The remaining supernatent was incubated with 250µl packed Ni+ 
NTA agarose beads (Qiagen, 30210) per 10ml supernatent for 2 hours at 4°C on a 
rotator. Beads were prewashed 3 times Ni+ NTA wash buffer prior to incubation. 
Following this, a 50µl sample of supernatent was taken to analysis the efficiency of 
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the affinity purification; depleted fraction. Beads were then washed 3 times with Ni+ 
NTA wash buffer and made into a 1:1 slurry in Ni+ NTA wash buffer for storage. Both 
extracts fragments and 20µl of 1:1 beads were denatured at 95°C for 5 minutes in 
5X Laemmli Sample Buffer and resolved by SDS-PAGE as an assessment of the 
purification.  
To elute protein from the beads, 100µl packed beads were incubated in 400µl elution 
buffer on ice for 1 min. Beads were then centrifuged at 200g, 3min at 4°C and the 
supernatent was retained. This was repeated and supernatents were pooled. The 
total volume of supernantent was made up to 5ml with Ni+ NTA lysis buffer, lacking 
phosphatase and protease inhibitors, in order to dilute the imidazole.  To concentrate 
the proteins and pass out the imidazole, the solution as then diafiltrated using an 
Amicon Ultra-4 Centrifugal Filter Unit with Ultracel-10kDa (Merck 
Millipore; UFC801096); the solution was added and then centrifuged at 3220g for 
10min at RT. The volume of retained solution was again increased to 5ml and 
centrifuged and previously done. The retained protein solution was then mixed with 
10% glycerol and alloquoted for storage at -80°C.  
2.7 Purification GST-USP7 and GST-USP11 from Rosetta 
Bacteria using glutathione 4B Sepharose beads 
In order to purify GST-USP7 and GST-USP11, previously mentioned plasmids were 
used in conjunction with an adapted protocol as stated by the author(35). Rosetta 
bacteria were transformed using pGM-GST-USP7 or pGM-GST-USP11 according 
the suppliers recommendations. Single colonies were used to inoculate 50ml of 
liquid broth. These starter cultures were incubated overnight at 37°C, 200rpm. 10ml 
of this culture was used to inoculate 4x500ml LB broth, per USP, giving a total of 2L 
each. Cultures were propagated at 37°C, 200rpm to an optical density (OD) of 0.4-
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0.6. Plasmid expression was then stimulated in each culture with the additional of 
1mM IPTG. Cultures were then incubated overnight at 18°C, 200rpm and then 
centrifuged at 4000g for 20min at 4°C. Bacterial pellets were resuspended in 
glutathione sepharose lysis and sonicated twice on ice for 10s at 40% amplitude. 
Lysates were then incubated on ice with 1mg/ml lysozyme for 10min and then 
centrifuged at 20,000g for 20min at 4°C. After this step, soluble and depleted 
fractions were maintained as previously done when purifying His-SUMO PRMT1v2. 
The resulting supernatent for each protein was then incubated with glutathione 
sepharose 4B beads (GE Healthcare 17-0756-01), at a ratio of 600µl packed beads 
to 10ml supernatent, for 2 hours at 4°C on a rotator. Beads were prewashed 3 times 
in glutathione sepharose lysis buffer prior to incubation. Following incubation, beads 
were washed 3 times with wash buffer and made into a 1:1 slurry, in wash buffer, for 
storage at 4°C. All removed fractions and 20µl of 1:1 beads were denatured at 95°C 
for 5 minutes 5X Laemmli sample buffer and resolved by SDS-PAGE as an 
assessment of the purification.  
2.8 Pull-Down Assay 
The following procedure was used to assess protein interactions between PRMT1v2 
and USPs. 10µl packed USP-conjugated glutathione sepharose 4B beads were used 
for each separate experiment. 2µl of GST-conjugated beads, which were already 
available in the Davies lab, was used for controls. Beads were washed twice with 
their experimental incubation buffer then resuspended in 500µl of the same buffer 
containing 10µg/ml leupeptin and aprotinin. 4µg His-SUMO-PRMT1v2 was added to 
pull-down solutions where necessary. Pull-downs were then rotated at 4°C for 1 
hour. Beads from each condition were centrifuged at 200g, 5min at 4°C and washed 
4 times in incubation buffer. All residual buffer was removed using a fine-gauge 
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insulin syringe. Beads were denatured at 95°C for 5 minutes in 40µl Laemmli sample 
buffer. Each sample was dividing equally between a 10% and 12% acrylamide gel. 
For each gel, 200ng His-SUMO-PRMT1v2 was added to 13µl sterilised distilled 
water and denatured in 4µl Laemmli sample buffer and loaded as an input. All 
samples were resolved by SDS-PAGE. Bands from the 12% gel were then visualised 
using coomassie staining and those of the 10% gel were transfered to a 
Polyvinylidene fluoride (PVDF) membrane and subjected to western blotting.  
2.9 SDS-PAGE  
SDS-PAGE procedures were carried out using the BioRad Mini-PROTEAN Tetral 
Cell minigel electrophoresis system (165-8004). Acrylamide gel mixtures were made 
according to table 6, whilst withholding APS and TEMED. These reagents were 
added to mixtures immediately before pouring.  7.5-8ml of gel mixture was poured 
into the systems casting module. 1ml isopropanol was layered on top to exclude air  
bubbles and create a level surface. After polymerisation, the isoproanl layer was 
washed off with ddH20, the stacking gel poured on top and combs inserted. 
Denatured samples were loaded into appropriate lanes. 2µl of Geneflow BLUeye 
Prestained protein ladder (S6-0024) was loaded separately as a marker. Gels were 
run at 125V for at least 90 min in 1X running buffer. For pull-down experiments, it 
was ensured that larger proteins GST-USP11 and GST-USP7 (110kDa and 130kDa 
respectively) migrate out of the stacking gel, whilst retaining the smaller GST in the 
resolving gel. Protein bands were then visualised using coomassie staining or 





2.10 Coomassie Staining 
All staining procedures were conducted on a rocker at room temperature. Acrylamide 
gels were fixed for 10min in fixing solution, stained with coomassie blue solution for 
5min and then destained for at least 2 hours in destaining solution before being 
imaged using a Peqlab FUSION FX7 Advance chemiluminescence imager. 
2.11 Protein Transfer, Western Blotting and Enhanced 
Chemoluminescence  
Hybond-P PVDF membranes (GE Healthcare Life Sciences, RPN303F) were used 
for protein transfer.  Membranes were first activated in MeOH for 10sec, washed in 
distilled water for 2min and then equilibrated in transfer buffer for at least 5min prior 
to transfer. Acrylamide gels were also soaked in transfer before for at least 5min. 
Gel Category Component Concentration 
Resolving  
Tris 375mM 
Acrylamide 8, 10 or 12% (v/v) 









Acrylamide 5% (v/v) 
 SDS 0.1%  (w/v) 
 APS 0.1% (w/v) 
TEMED 0.1% (v/v) 
Table 6: Components of polyacrylamide gels. Percentage of acrylamide used was altered 
according to the molecular weights of the proteins visualised; smaller percentages were used when 
visualising larger proteins, e.g. GST-USP11 and GST-USP7, and vice versa.  
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Protein bands were transferred using the Bio-Rad Trans-blot Turbo semi-dry transfer 
system at 25V for 25 min. Membranes were blocked in TBST with 5% (w/v) milk 
powder for at least one hour. After being briefly washed in TBST, membranes were 
incubated with rabbit anti-PRMT1 primary antibody in 5% BSA (w/v) overnight at 
4°C. Membranes were then washed 3 times for at least 5 min each in TBST and then 
incubated in HRP-conjugated goat anti-rabbit secondary antibody in TBST 5% (w/v) 
milk powder, for 1 hour, RT. Blot was then washed in TBST as before and then 
treated with SuperSignal West Dura Enhanced chemiluminescence (ECL) HRP 
substrate(Thermo Scientific). Protein bands were then viewed using Amersham 















3.1 PRMT1v2 was cloned into pET28 His-SUMO background 
In order to determine if PRMT1v2 interacts directly with USP11 or USP7, it was 
necessary to create tagged-recombinant proteins to be used for pull-down 
experiments. It was decided to clone PRMT1v2 as this isoform contains the addition 
18 amino acids of exon 2. Furthermore, the prevalence of v2 in breast cancer 
tumourigenesis makes it a more relevant candidate for understanding its methods of 
regulation (15). The Davies lab had previously received plasmid constructs encoding 
GST-tagged, full-length versions of USP11 and USP7, as a kind gift from Goedele 
Maertens (35). As such, it was decided that His-tagged PRMT1 expression 
constructs would be generated. To this end, PRMT1v2 was PCR amplified, using 
GFP-PRMT1v2 as a template (see Materials and Methods) and cloned into pET28-
His-SUMO, containing kanamycin resistance. The addition of an N-terminal SUMO 
tag is well known to increase the solubility and expression of eukaryotic proteins in 
E. coli(48). Cloning was conducted using the DH5α bacterial strain, which were then 
plated on kanamycin-containing agar plates. Colonies were then picked and used to 
inoculate starter cultures in liquid broth. Cultures were incubated overnight and DNA 
was extracted from cultures using the Omegabiotek Minikit according to the 







To identify positive clones, where successful plasmid ligation had occurred, 
extracted DNA was subjected to restriction endonuclease digest, using BamH1 and 
Not1, followed by separation through agarose electrophoresis. 1% agarose gels 
were made with ethidium bromide in order to visualise DNA bands using ultraviolet 
light (Figure 7). DNA prepared from each of the 6 bacterial colonies each yielded two 
bands following resolution; a 0.8kb band, representing the PRMT1v2 insert, and a 
second, approximately 5.3kb, representing the pET28-His-SUMO vector. This shows 
that PRMT1v2 was correctly cloned into pET28-His-SUMO. Remaining DNA 
extracted from the bacteria was pooled, alloquoted and frozen at -80°C for storage.  
3.2 Generation of Recombinant His-SUMO-PRMT1v2 
Having generated the pET28-His-SUMO-PRMT1v2 expression plasmid, it was 
subsequently used to transform bacteria, from which to extract recombinant protein. 
To increase the resemblance of this exogenous protein to wild-type proteins 
generated in eukaryotes, Rosetta BL21 strain bacteria were used for 
transformations. This strain provided tRNAs for codons which are a rare in bacteria, 
thus enhancing the accuracy and expression of eukaryotic proteins. Bacteria were 
transformed with pET28-His-SUMO-PRMT1v2 and grown on kanamycin agar plates. 
A colony from these plates was picked and used to generate a 2L liquid culture with 
an OD of 0.6 (See materials and methods). Plasmid expression was induced with 
IPTG and cultures were then propagated further, as per materials and methods, 
before being harvested by centrifugation. Recombinant proteins were isolated from 
sonicated bacterial lysates by affinity purification using Ni+ NTA beads. Fractions 
were taken from lysates before and after incubation with beads, the soluble and 
depleted fractions respectively. Proteins were then eluted from the beads using a 
high concentration of imidazole. To concentrate the protein solution and dialyse 
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against the high molarity imidazole required for the solution, the protein-imidazole 
solution was diafiltrated twice using a filtration column which retains proteins larger 
than 10kDa. The presence of His-SUMO-PRMT1v2, both attached to beads and 
purified, was confirmed using SDS-PAGE and coomassie staining (Figure 8A). 
Fractions were run along-side as an assessment of recombinant protein solubility 
and the quality of the purification. Multiple proteins were seen attached to the beads, 
suggesting the purification is highly impure. These are likely proteins with exposed 
histidine residues or degraded recombinant proteins. However, the strongest band 
seen for both purified and bead-conjugated protein was in the region of 50kDA. 
PRMT1v2 has a molecular weight of approximately 42.5kDa, where as the SUMO 
tag is 8kDA. This suggests that this 50kDa band is His-SUMO-PRMT1v2 and that 
had successfully been purified. Furthermore, corresponding bands of similar 
intensities are seen for both eluted and conjugated proteins, suggesting that the 
elution process was highly efficient. Disappointingly, the recombinant protein band is 
of a similar strength to proteins within both fragments, implying weak expression of 
the plasmid. Concurrent with this, the corresponding 50kDa band seen in both 
fractions is faint suggesting that His-SUMO-PRMT1v2 may have low solubility.  
Nevertheless, as His-SUMO-PRMT1v2 is the predominant eluted protein, this 















Figure 7: Agarose electrophoresis of DNA digests extracted from bacterial clones 
transformed with pET28-His-SUMO PRMTv1:PRMT1v2 was cloned into pET28 His-SUMO vector. 
This plasmid was used to transform super-competent DH5α Rosetta™ bacteria (Bioline), which were 
then plated on kanamyocin containing agar. DNA was purified from successfully transformed 
colonies, using a miniprep kit (Omega Biotek). DNA was then digested using BamH1-HF and Not1-
HF restriction endonucleases. The resulting DNA was resolved using electrophoresis. Each lane 
represents an individual bacterial colony from which DNA was extracted using the miniprep kit.  
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3.3 Generation of GST-USP11 and GST-USP7 conjugated to 
glutathione Sepharose 4B Beads 
Purification of recombinant GST-USP11 and GST-USP7 was achieved  by adapting 
a protocol previously established by Goedele Maertens et al, 2010(35).To aid this, 
plasmids coding for GST-tagged versions of both enzymes had been generously 
donated by the same author. These were used to transform to Rosetta bacteria as 
previously done with His-SUMO-PRMT1v2. Transformed bacteria were grown on 
ampicillin agar plates. Single colonies for each transformation were picked and used 
to develop 2L liquid agar cultures. Plasmid expression was induced in these cultures 
with IPTG once they had reached an OD of 0.6. Cultures were then propagated, 
centrifuged and lysed as per materials and methods. Recombinant proteins, 
containing GST, were isolated from lysates with glutathione sepharose 4B beads. 
Soluble and depleted fractions were taken from lysates as previously done when 
isolating His-SUMO-PRMT1v2. The beads were then washed and refrigerated at 4°C 
for storage as 1:1 slurry in wash buffer. Fractions and samples of beads for each 
protein were then resolved using SDS-PAGE. Gels were then coomassie stained to 
assess the quality of purification (Figure 8B).  
Protein yields for GST-USP11 and GST-USP11 were small, however the shear sizes 
of these proteins (136kDa and 156kDa respectively) make bacterial expression 
difficult. Consequently, several proteins are seen attached to both sets of beads, 
which are likely degradation products of recombinant proteins. Furthermore, the 
GST-USP11 yielded 2 particularly strong non-specific bands at approximately 55kDa 
and 85kDa, which could decrease the authenticity of any interactions observed from 
later experiments (Figure 8B).  However, relatively strong bands corresponding to 
the sizes of GST-USP11 and GST-USP7 were observed from their respective 
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purifications, suggesting the preparation was successful. These preparations were 
subsequently used to assess the interactions between these enzymes and 
PRMT1v2.  
3.4 Pull-down assays suggest that PRMT1v2 interacts directly 
with both USP11 and USP7 in vitro 
Pull-down assays were performed to assess whether PRMT1v2 could interact 
directly with USP11, USP7 or both. Glutathione sepharose 4B-bound forms of GST-
USP11 or GST-USP7 were incubated with or without purified His-SUMO-PRMT1v2 
for 1 hour at 4°C. As the stringency of these interactions was unknown, each pull-
down was performed in phosphate buffered saline (PBS) or in buffer physiological 
levels of NaCl (150mM). Beads were washed and denatured for resolution by SDS-
PAGE. Each sample was divided between 2 gels. One was visualised by coomassie 
stain and the other was subjected to protein transfer to a PVDF membrane, followed 
by anti-PRMT1 western blotting (Figure 9A). An input of His-SUMO-PRMT1v2 alone 
was run on the gel subjected to western blotting, as a positive control for the 
antibody. Band patterns resembling those seen for the purification of GST-USPs 
were visible on the Coomassie stained gel. This showed that both GST-USP11 and 
GST-USP7 were present throughout the pull-down and that they were not lost as a 
consequence of technical error. Moreover, PRMT1 bands were not seen for pull-
downs where His-SUMO-PRMT1 was not added, which shows the specificity of the 






















Figure 8: Coomassie blue stains showing stages of protein purification for His-SUMO-PRMT1v2, GST-USP11 
and GST-USP7: Rosetta™ super-competent DH5α bacteria were transformed with plasmids expressing the required 
protein. Two litre liquid cultures for each protein were cultured to an OD of 0.6. Protein synthesis was induced with 
IPTG and cultures were allowed to grow for a set specific for each protein. Cells were lysed and each protein was 
extracted from supernatents. Samples were taken from supernatents before (Soluble Fraction; SF) and after 
(Depleted fraction; DF) incubation with beads to ensure the presence of proteins in the supernatent and to observe 
the effect of the beads.  A: Purification of His-SUMO-PRMTv2. Cultures were incubated for a further 5 hours at 
37°C before harvesting. Bacterial lysates were incubated with Ni
+
 NTA beads for 2 hours. Beads were then washed 
and a sample was taken for SDS-PAGE. Half of the beads were incubated with buffer containing a high 
concentration of imidazole in order to elute protein from the beads. The buffer was passed through a filtration column 
in order to concentrate the protein. A sample from this protein solution was subjected to SDS-PAGE. B Purification 
of GST-USP11 and GST-USP7. Cultures were incubated overnight at 18°C before harvesting. Bacterial lysates were 






However, with the addition of His-SUMO-PRMT1v2 to GST-USP11 and GST-USP7, 
a clear 50 kDa band, consistent with the size of this His-SUMO-PRMT1v2 PRMT1, 
was apparent suggesting that PRMT1v2 interacts directly with USP11 and USP7 
(Figure 9A). This band was present in pull-downs conducted in both and 150mM 
NaCl buffers; however PRMT1v2 binding to USP11/7 was substantially reduced in 
150mM NaCl, reflecting the more stringent conditions of this buffer. This shows that 
potentially both enzymes are capable of directly interacting with PRMT1v2. Further 
anti-His or anti-SUMO immunoblotting using the samples could have been used to 
confirm the identity of this 50kDa band,  
To further confirm the occurrence of these interactions and investigate the specificity 
of these interactions, each pull down was repeated at different concentrations of 
NaCl (150, 250 or 400mM). A third pull-down using beads conjugated to GST alone 
was included as a negative control (purified protein already available in the Davies 
lab) (Figure 9B). A large 26kDa band was seen on the coomassie stained gel which 
denotes the high concentration of GST used in the reaction. However, despite the 
substantial proportion of GST utilised, a negligible signal for His-SUMO-PRMT1v2 is 
seen for the pull-down conducted at 150mM NaCl. Furthermore, the interactions 
previously seen at 150mM for GST-USP11 and GST-US7 have repeated. Together 
this shows that the observed interactions are highly specific for these USPs. As 
expected, bands representing PRMT1v2 are not seen at salt concentrations above 
the physiological level. This suggests that the observed reactions are physiologically 
relevant and may occur in vivo. In conclusion, these results provide evidence that 

























Figure 9: Western blot and Coomassie stain analysis of pull-down assays assessing interactions of 
PRMT1v2 with USP11 and USP7 at different salt concentrations: Glutathione sepharose 4B beads 
conjugated to GST-USP11 or GST-USP7 were was incubated with or without His-SUMO-PRMT1v2 for 1 hour 
at 4°C. Beads were then washed and denatured for SDS-PAGE. Each sample was divided between 2 
acrylamide gels. One gel underwent coomasie staining, whereas the other was subjected to western blot 
analysis using an anti-PRMT1 antibody. A: Pull-down assays conducted in PBS and physiological levels 
of NaCl (150mM): An input comprising His-SUMO-PRMT1 alone was added to the first lane as a positive 
control for the primary antibody. B Pull-down down assays conducted at 150, 250 or 400mM NaCl. A third 





4.1 Summary of Results 
 
 PRMT1 variant 2 is capable of direct interaction with both USP11 and USP7.  
 Interactions between PRMT1v2 and USP11/7 are lost at non-physiological 
salt levels, suggesting this reaction can occur in vivo.  
4.2 The physiological role of the direct interaction 
4.2.1 Does PRMT1 methylate USP11 and USP7? 
Probably the most immediate question raised in response to these findings is as to 
whether USP11 and USP7 are methylated by PRMT1. PRMT1 is thought to target 
proteins containing RGG/RG repeats for methylation (4). Such motifs are present in 
the primary sequence of USP7, but not in USP11 (Figure 10). However, this is not to 
say that PRMT1 cannot methylate USP11, as many validated PRMT1 substrates are 
methylated independently of an RGG/RG motif (5). Furthermore, the TAP-tag assay 
previously used to discover USP11 as an interactor for PRMT1 used a 
methyltransferase dead PRMT1v1 as a bait protein. Not only does this suggest that 
the inclusion of exon 2 is not required for this interaction, but it is supports the notion 
that USP11 may be a methylated substrate of PRMT1. It is surprising that this initial 
investigation did not show USP7 as an interactor, as it possesses an RGG/RG motif 
with mice and humans. Furthermore, this RG motif is found within the catalytic 
domain (UniProt database), which implies that arginine-methylation of this motif 
could influence its deubiquitylase activity. However, the TAP-tag assay is a stringent 
investigation tool, due to the two rounds of affinity purification. As such, weak or 
transient interactions are sometimes lost throughout its proceedings, which may 
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explain why USP7 was not originally discovered. In total, it can be said that USP11 




Figure 10: Amino acid sequences of Homo sapien USP7 and USP11. RGG/RG of USP7 
is highlighted in red. Source: www.pubmed.gov 
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Further investigation is necessary to elucidate as to whether USP7 and USP11 are 
methylated by PRMT1. Employing both in vitro and in vivo methylation assays will be 
of great benefit. In vitro assays employ the use of radioactively labelled SAM ([3H]-
SAM) as a catalyst for methylation by PRMT1 (49). As such, recombinant PRMT1 is 
incubated with potential recombinant substrates and [3H]-SAM. True substrates will 
become radioactively labelled, which can be visualised by SDS-PAGE and 
fluorography. The purified versions of His-SUMO-PRMT1v2, GST-USP11 and GST-
USP7 could be used within this assay to assess their methylation status. To 
determine if methylation occurs within cells, in vitro findings should be confirmed with 
in vivo methylation assays. Cell lines can be first treated with adenosine dialdehyde 
(AdOx) to expose potential methylation sites and cycloheximine to block de novo 
protein synthesis, and then cultured in media containing [3H] methylmethionine (50). 
Through the methionine metabolic pathway, tritium becomes encorporated into 
endogenous SAM and methylated proteins labelled. Specific methylation of the 
protein of interest is achieved through immunoprecipitation, separation via SDS-
PAGE and fluorography. Importantly, through the inhibition of de novo protein 
synthesis, radiolabelled methyl groups can only be encorporated as a PTM, hence 
the radiolabelling is a reflection on methyltransferase activity rather than the 
incorporation of radiolabelled methionine into translated proteins. Repeating these 
procedures in the presence of siPRMT1 will confirm that PRMT1 is responsible for 
this methylation. Functional assays for USP activity would be required following this 
to determine the functional significance of arginine methylation. For example, USP7 
or USP11 could be incubated with known substrates, such as p53 and ALK5 
respectively (45, 46). Substrate stability could be determined through SDS-PAGE 
and western blotting under conditions where PRMT1 is present or absent.  
52 
 
4.2.2 Do USP11 and USP7 regulate the activity and stability of PRMT1?  
Although the TAP-tag assay previously used in the Davies lab was initially optimised 
to identify novel methylated substrates of PRMT1, it is a possibility that interactions 
between USP11 and USP7 may be concerned with regulating the activity of PRMT1. 
One clear mechanism in which this may occur is through deubitiquitylation. 
Information as to if PRMT1 is ubiquitylated is lacking. Deubiquitylation of K48-linked 
chains however could lead to the stabilisation of PRMT1. At the end of this 
investigation, the half-life of PRMT1 was assessed using separate treatments of 
HEK293T cells with cycloheximide or MG132 to inhibit protein synthesis and 
proteasomal degradation, respectively (data not shown). Subsequent anti-PRMT1 
western blot analysis of cell lysates showed persisting PRMT1 bands for up to 10 
hours following these treatments, suggesting that PRMT1 is a highly stable protein 
and that half-life experiments would need to be conducted using 35S-labelled 
methionine. Furthermore, after the completion of this project, the Davies lab has now 
shown that overexpression of USP11 and USP7 increases protein levels of PRMT1. 
Future work will be needed as to determine if these observations are caused by 








USP11/7 may regulate the activity of PRMT1, or vice versa, through none-enzymatic 
association and protein complex formation. Although this investigation has shown 
that both USP11 and USP7 interact directly with PRMT1, it is not known if each 
protein interacts separately with PRMT1, or if the three proteins form a tertiary 
complex (Figure 11). This would largely depend on the spatiotemporal qualities of 
each DUB. USP7 was not identified as a substrate of PRMT1 through TAP-tag 
affinity purification. Evidence which explains this finding supports a non-enzymatic 
regulation between these two proteins. For example, it suggests that USP7 is not 
methylated but can still interact with PRMT1. In support of this, a study has outlined 
a consensus amino acid sequence for the recognition of interactors by USP7 (47). 
Multiple sequences of P/AXXS were found to be important for USP7 recognition of 
p53 and MDM2 (47). Such a sequence is found in PRMT1v1 and PRMT1v2 (Figure 
12), which represents a prime candidate for the interaction site between USP7 and 
PRMT1. Interestingly, the best described positive regulator of PRMT1, BTG1, also 
possesses two P/AXXS motifs (Figure 12). USP7 may therefore regulate the activity 
of PRMT1 through direct interactions but also through the control of BTG1.  As such, 
USP7 may be targeted to PRMT1 by BTG1 or vice versa. Site-directed mutagenesis 
of these residues will confirm their importance in USP7-PRMT1 association and the 












Figure 11: Schematic displaying potential models of PRMT1 interactions with USP11 
and USP7.  
Figure 12: Amino acid sequences of Homo sapien PRMT1v1 and BTG1. Potential USP7-




4.3 Do PRMT1 splice variants interact differently with USP11 
and USP7? 
Functional differences in the activity between PRMT1v1 and PRMT1v2 are evident, 
both in normal physiology and tumourigenesis (15). This is mostly likely due to their 
specific localisations. These differences may give some insight as to the 
spatiotemporal organisation of USP11 and USP7. Both enzymes are predominantly 
nuclear and 50% of USP7 is chromatin bound (35). PRMT1 is commonly chromatin-
bound in order to co-activate nuclear receptor-induced gene transcription though 
histone H4R3 methylation (12, 13, 16). It is possible that USP7 or USP11 interaction 
may be necessary for PRMT1 control of gene expression. More specifically, these 
proteins may predominantly associate with PRMT1v1 due its nuclear localisation. 
This is not to say that they cannot interact with other isoforms. USP11 is also found 
in the cytoplasm, which is necessary for deubiquitylation of ALK5 and promoting 
TGFβ signalling (45). In this instance, USP11 may interact solely with the 
cytoplasmic PRMT1v2. In support of this, it has been shown that PRMT1 methylates 
Smad6, which causes its relocalisation to BMP-receptors (51). PRMT1v2 was also 
shown to associate at type II BMP-receptors. Both USP11 and PRMT1v2 have been 
separately shown to associate at these receptors and promote TGFβ signalling(45, 
51). PRMT1 may also interact simultaneously with both USPs under certain 
circumstances. For example, PRMT1 interaction may regulate the repression of 
Ink4a by chromatin-bound USP11 and USP7 (35).  In conclusion it is likely that 
USP11 and USP7 individually interact with PRMT1 in response to specific signals. 
The specific isoform with which each interacts will likely depend on the 




4.4 Protocol Optimisation and Further Investigation 
4.4.1 Optimisation of protein purification protocols 
One of the most difficult challenges when conducting this investigation was the 
purification of GST-USP11 and GST-USP7. Both proteins are over 100kDa, thus 
ensuring accurate and stable exogenous expression was a challenge. As such, 
although full-length proteins were acquired, several products of degradation from 
these proteins were present on glutathione sepharose 4B beads. These impurities 
could have masked the true nature of the observed interactions, or perhaps created 
false-positive results through multiple, non-specific interaction with PRMT1. 
Technical challenges were even present upon completion of the purification. 
Following affinity purification, the beads became incredibly adhesive. This is likely 
due to, again, the number of impurities in each set of beads, or potentially the large 
size of the proteins giving rise to multiple non-specific reactions with free amino acid 
side chains. GST-USP11-conjugated beads were particularly adherent, potentially 
due to the strong 55kDA and 85kDa bands seen in the preparation. This made the 
beads difficult to handle and most likely caused protein to be lost as beads were 
washed. Furthermore, this may have restricted the movement of the beads during 
the pull-down incubation.  
Smaller proteins are much easier to purify and are often expressed at higher 
proportions in the soluble fraction. For that reason, it would be beneficial to repeat 
these proceedings using plasmids that encode fragments of USP11 and USP7. 
Using smaller proteins would increase protein solubility, bacterial expression and 
reduce the impurity of each preparation. In addition, repeating these processes using 
sequential, overlapping peptides of each USP’s sequence, important motifs and 
residues could be identified and the binding site could be mapped. The findings from 
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this could then be elucidated further using x-ray crystallography and site-directed 
mutagenesis. This technique may also be used in tandem with in vitro and in vivo 
methylation assays, in order to identify and map methylated arginine residues. Such 
actions would improve the quality of this investigation and increase our molecular 
understanding of these interactions. 
4.5 Targeting the interaction between USP11 and USP7 for 
the treatment of breast cancer 
Although the nature and purpose of the direct interactions of PRMT1 with both 
USP11 and USP7 have yet to be elucidated, it is conceivable that the invention of 
such events could be of therapeutic importance. One possibility is that PRMT1 is 
deubiquitylated and stabilised by USP11 and USP7. Alternatively, the association of 
PRMT1 with these proteases, either for methylation or direct regulation, may 
contribute to the tumourigenic actions of either protein. In either case, the inhibition 
of these interactions could be employed for an anti-cancer therapy.  PRMT1 is 
thought to contribute to the progression of ERα-dependent breast cancer, and has is 
also found upregulated in other tumours (19, 25). As such several studies have been 
devoted to the discovery of PRMT1-specific inhibitors (52, 53). Of importance, it is 
not certain how PRMT1 inhibition would affect patients. Due to the diverse activities 
of PRMT1, its inhibition could yield many side-effects, although a reduction to normal 
expression levels could be of benefit for cancer patients. In addition, achieving 
PRMT1-specificity is challenging due to the similarities in activity between PRMT 
family members. Targeting USP11 and USP7 for inhibition presents similar 
problems. Evidence suggests that a decrease in USP7 activity would induce p53 
destabilisation and a complete removal would cause p53-induced senescence (46). 
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A loss of USP11 may also promote further tumourigenesis through increased 
frequency of DSB and increased NFκB activity (42-44).  
Exclusive intervention of PRMT-USP interactions, possibly through use of by small 
interfering molecules or peptides could be of therapeutic value. Specific inhibition of 
the interactions described in this investigation could reduce the activities of PRMT1, 
either through a reduction in protein stability or regulation by interactors. As we have 
shown that PRMT1 is highly stable, coupled to the likely presence of other regulatory 
processes, interrupting these reactions would probably preserve its baseline function 
in cellular homeostasis. Importantly, the necessary activities of both USP11 and 
USP7 would also be preserved, which would limit the overall side-effects of this 
treatment. Although further insight into the mechanics and consequences of the 
interactions between PRMT1, USP11 and USP7 will be required before such 
procedures can come into fruition, this investigation has uncovered a potentially 
important relationship involving PRMT1 which could be exploited for treatment of 
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APPENDIX: LIST OF ABBREVIATIONS  
Abbreviation Meaning 
53BP1 p53 Binding Protein 1 
ADMA Asymmetric Dimethylated Arginine  
ALK Anaplastic lymphoma kinase  
AP-1 Activator Protein-1 
APC Adenomatosis Polyposis Coli 
APS Ammonium Persulphate  
BMI-1 B cell-specific Moloney murine leukemia virus integration site 1 
BTG1 B-cell translocation genes 1  
BTG2 B-cell translocation genes 2 
CBP Calmodulin Binding Protein  
CK1 Casein Kinase 1 
CRM1 Exportin-1 
DNA Deoxyribonucleic acid 
DSB Double Strand Breaks 
DTT Dithiotheitol 
DUB Deubiquitylase 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
EMT Epithelial-Mesenchymal Transition 
ERE Oestrogen Response Elements  
ERα Oestrogen Receptorα 
GFP Green Fluorescent Protein 
GSK3β Glycogen Synthase Kinase 3β 
63 
 
GST Glutathione S-Transferase 
H4R3 Histone 4 Arginine 3 
H5K5 Histone 4 Lysine 5 
HA Haemagglutinin 
HAUSP Herpes-virus-associated Ubiquitin-Specific Protease 
hCAF1 CCR4-associated factor  
HEK293T Human Embryonic Kidney 293 with T antigen  
His 6 Histidine Tag 
hnRNP Heterogeneous Nuclear Ribonucleoprotein  
HRP Horseraddish peroxidise 
IgG Immunoglobulin G 
INK4a/ARF  Inhibitor of cyclin-dependent Kinase type 4/Alternate Reading Frame 
IP Immunoprecipitation  
IPTG Isopropyl β-D-1-thiogalactopyranoside  
ISG15 Interferon-induced 17 kDa protein 
LB Liquid Broth  
LRP-5,6 Lipoprotein Receptor-related Protein 5,6  
MAPK Mitogen-activated Protein Kinase  
MCF7 Cells Michigan Cancer Foundation-7 Cells 
MCM-BP Minichromosome Maintenance Binding-Protein  
MD Methyltransferase-dead  
MDM2 Mouse double minute 2 homolog  
MDMX Mouse double minute X homolog  
MEF Mouse Embryonic Fibroblast 
MLL Multilineage Leukaemia 
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MMA Monomethylated arginine  
MS Mass Spectrometry  
NTA Nitrilotriacetic Acid 
PBS Phosphate buffer solution 
PcG Polycomb Group 
PCR Polymerase Chain Reaction  
PGC-1α Peroxisome Proliferator-activated Receptor γ coactivator-1α 
PI3K Phosphatidylinositol-3-kinase  
PMSF Phenylmethanesulfonylfluoride 
PRMT Protein Arginine Methyltransferase 
PTM Post-Translational Modification 
PVDF Polyvinylidene Fluoride 
RACO-1 RING domain activator AP-1 coactivator-1  
RGG/RG  Arginine-glycine-glycine/Arginine-glycine 
RING Really Interesting New Gene 
RNAi Ribonucleic Acid interference  
RT Room Temperature 
SAM S-Adenosylmethionine  
SAM68 Src-Associated substrate in Mitosis of 68 kDa 
SDMA  Symmetric Dimethylated Arginine  
SDS-PAGE Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis  
siRNA Small Interfering Ribonucleic Acid 
SOC Super Optimal broth with Catabolite repression  
STAT Signal transducer and activator of transcription 




TAP Tandem Affinity Purification 
TBS Tris Buffered Saline  
TBST Tris Buffered Saline Tween 
TCF-LEF T-cell factor/lymphoid enhancer factor 
TEMED Tetramethylethylenediamine 
TEV Tobacco Etch Virus 
TGF Transforming growth factor 
THW Threonine-Histidine-Trytophan 
tRNA Transfer Ribonucleic Acid 
USP Ubiquitin Specific Protease 
Wnt Wingless-Int 
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Several investigations show how tumour cells can engulf live cells through entosis, 
generating cell-in-cell structures. This generates large intracellular vesicles which 
obstruct cytokinesis, resulting in binucleate, tetraploid cells. Polyploidisation is often 
associated with tumourigenesis, yet this is not known in the liver. However 
polyploidy, aneuploidy and multinucleation have been observed in hepatocytes. The 
origin and functional significance of this is not clear. Hepatocytes are also known to 
conduct phagocytosis. Evidence exists which implicates phagocytosis in the 
generation of polyploid cells. To investigate if hepatocyte phagocytosis affects ploidy, 
we used Huh-7 hepatoma cells as a model of hepatocytes and induced 
differentiation following consecutive rounds of phagocytosis of heat-killed 
lymphomas and hepatomas. Significant increases in multinucleation were observed 
following three rounds of phagocytosis. Surprisingly, prolonged phagocytosis 
generated differentiated, non-dividing Huh-7 subsets. In addition, it was confirmed 
that primary human hepatocytes are capable of phagocytosing heat-killed 
lymphomas. Finally, we developed a de novo double-staining technique for 
simultaneous identification of apoptosis and lymphocytes in diseased liver sections. 
This paves the way for new investigations to enhance our understanding of the 
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1.1 Cell-in cell structures and ploidy  
In recent years several lines of evidence have come to light which depict the 
generation of polyploidy cells due to the creation of the so-called ‘cell-in-cell’ 
structures (1). This describes the creation of large intracellular vacuoles, which 
contain live cells which have been ingested whole. This process of live-cell 
engulfment, known as entosis, has been studied in depth by the Overholtzer lab (2, 
3). This group originally observed that metastatic breast cancer cell-lines were 
capable of engulfing members of the same cell line (2). Additionally, it appeared that 
live cells invaded others through an active process which was dependent on Rho 
GTPase signalling. As 70% of these internalised cells died as a result of this 
internalisation, entosis was defined as a method of cell death. However, other cells 
were shown to exit the cell and continue normal cellular processes, showing that 
entosis merely described the internalisation of live cells. The same study had also 
revealed the presence of entosis in primary human breast cancers, showing that this 
was a physiologically relevant process (2). Subsequent research by the same group 
revealed that the presence of this entotic vesicle could give rise to the formation of 
polyploid cells (Figure 1A) (3). Analysis of tumour cells possessing cell-in-cell 
structures revealed that 60% of such cells possess more than one nucleus. Further 
investigation utilising ectopic expression of fluorescently-tagged cytoskeletal proteins 
demonstrated that cell-in-cell structures could impose a physical block on the 
cytokinetic cleavage furrow (Figure 1B). This would lead to asymmetric cell division, 
generating binucleate, tetraploid daughter cells. Such cells would often experience 
subsequent dysregulation of cell divisions, resulting in cells with an incorrect number 
of chromosomes, known as aneuploid cells. The evidence displayed here suggested 
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that tumours could obtain polyploidy and further genomic instability through 
internalisation of their neighbours. This was dependent on cells becoming anchorage 
independent, a common feature of progressed tumours (2, 3). As such, the 
generation of cell-in-cell structures represented a remarkable new mechanism which 
elicits profound effects on the host cell and can often lead to the generation of 










Figure 1: Entosis of breast cancer cells by their neighbours resulting in asymmetric 
division, failure of cytokinesis and multinucleation. A: Time-lapse differential interference 
contrast and fluorescent micrographs of dividing MCF10A breast cancer cells containing a 
cell-in-cell structure. MCF10A cells expressing E-cadherin-GFP and histone H2B-mCherry were 
propagated in soft agar, 3-D cultures. Cells were imaged from the beginning of entosis to the end of 
attempted cell division. B Time-lapsed images of MCF10A cells displaying how cell-in-cell 
structures inhibit cytokinetic furrowing. MCF10A cells expressing GFP-tubulin were 
immunostained for myosin light chain in order to visualise the contractile ring associated with 
cytokinesis . White arrows highlight the cytoplasmic furrowing and contractile ring. Taken from 
Krajcovic et al¸ 2011 (3) 
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1.2 The creation and consequences of polyploidy 
 1.2.1 Creation of polyploid cells 
All normal somatic cells have a specific number of chromosomes within their nuclei 
which contain the required amount of genetic information for the development and 
functionality of the entire organism. The majority of eukaryotes obtain 2 sets of 
chromosomes from either parent, which results in all cells in body, excluding 
gametes, being diploid (2n). However, certain processes have been known to 
change the number of chromosomal sets within cells. Polyploidisation is well known 
to occur through heritable genetic abnormalities, derived from incorrect mitotic or 
meiotic divisions of gametes.  As such, the subsequent fusion of these gametes 
gives rise to daughter cells with an incorrect higher number of chromosomes (4). 
Increases in ploidy can also occur through cellular fusion, such as in the case of 
myofibril formation (5), or through the generation of multiple nuclei through failed 
cytokinesis.  
1.2.2 Consequences of polyploidy 
It is evident that an increase in the total number of chromosomes within cells is a 
natural, dynamic process, where cells can shift between different states of ploidy to 
achieve a state of highest fitness(6). Whole genome duplications can therefore 
contribute towards Darwinian selection as with any other genetic alternation. 
Increases in ploidy can therefore be advantageous for some cell times. Experiments 
conducted in yeast, for example, display how higher ploidy levels improve the ability 
of these cells to recover from DNA damage and degenerative mutation (7). This is 
the result of increased redundancy between genes due to increased copy numbers 
of each allele. Furthermore, possessing more than 2 copies of each allele can lead 
to the masking of harmful, recessive mutations and also presents opportunities for 
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phenotypic diversification.  However, the disadvantages of polyploidy have been 
commonly outlined in tumourigenesis. Polyploidisation is common in cancer; an 
increased risk of genomic instability is often advantageous for the developments of 
cancer cells (8). Tetraploid cells are commonly eliminated through p53-dependent 
apoptosis to prevent the survival unstable cells (9, 10).  However, this is not due to 
an endogenous tetraploidy detection system (11, 12). Furthermore, p53-mutations 
are common in cancerous cells making them prone to polyploidisation. Cancerous 
cells can benefit from the increased ploidy through increased copy numbers of 
mutant alleles which drive or propagate tumourigenesis. Furthermore, increased 
ploidy could increase the tolerance of cancerous cells to deleterious mutations, 
granting more time for the acquisition of oncogenes. Taken together, polyploidy can 
be advantageous to specific cell types, but may also enhance the risk of tumour 
progression. 
1.2.3 Failure of cytokinesis promotes polyploidy in cancers 
Failed cytokinesis is often implicated in tumourigenic polyploidy, often caused by 
dysregulated microtube organisation and failures at mitotic checkpoints. For 
example, Sotillo et al, showed how prolonged overexpression of Mad2 promoted 
aneuploidy and polyploidy in mouse embryonic fibroblasts (13). Mad2 is a key 
regulator of the spindle assembly checkpoint, which negatively regulates the cdc20-
anaphase promoting complex, ensuring that the cell cycle is continued without 
unattached chromosomal kinetochores. Its overexpression is common amongst 
human cancers, including liver cancer, and results in failed cytokinesis (13, 14). The 
frequency of polyploidy in human cancers as a result of failed cytokinesis is of 
particular interest to the investigation of cell-in-cell structures. Most cancers 
overcome the requirement of anchorage to the extracellular matrix (ECM) for 
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survival, propagation and migration, often through mimicking processes of the 
epithelial-mesenchymal transition (EMT). Furthermore, it was observed by 
Overholtzer et al, that breast cancer cells detach from the ECM prior to 
internalisation, which ultimately resulted in non-genetic cytokinetic failure (2). Taken 
together, it is plausible that polyploidisation is encouraged in tumour cells through 
the creation of cell-in-cell structures following detachment from the ECM.  
1.3 Hepatocytes are naturally polyploid 
1.3.1 The creation of polyploid hepatocytes  
The generation of polyploid cells through failed cytokinesis and multinucleation can 
occur within cancer cells and promote irregular cellular divisions. However, certain 
cells can naturally tolerate increases in chromosome number. Hepatocytes have 
commonly been observed possessing more than 2 sets of chromosomes (15). 
Hepatocytes are regenerative cells which comprise ~85% of total cells within the liver 
and conduct the majority of the organs primary functions, including the secretion of 
bile, metabolism and detoxification (16). Variations in the DNA content and the 
number of nuclei are a frequent occurrence amongst hepatocytes. Cells commonly 
exist as mononucleates or binucleates, with rare cases of larger hepatocytes 
possessing 3-4 nuclei (17). Increases in hepatocyte ploidy have been observed in an 
age dependent manner (18). This suggests that mechanisms for changes in ploidy 
occur accumulatively over time. It was shown that failure of cytokinesis occurs post-
natally in mouse livers, in a manner dependant on the Phosphatidylinotiside-3 
kinase/Akt (PI3K/Akt) signalling pathway (19). This suggests a mechanism of 
gradual increases in ploidy, whereby consecutive failed cytokinesis events generate 
binucleate, tetraploid cells. Such cells then undergo successful division, yielding 
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mononucleate, tetraploid daughter cells. These cells eventually fail cytokinesis a 
second time to generate octoploid cells and so on (Figure 2A).  
1.3.2 Functional significance of hepatocyte polyploidy 
It is not certain as to the purpose of multinucleate cells within the liver. One theory 
suggests that polyploid cells provide the regenerative capacity of the liver. In support 
of this, polyploid hepatocytes have been shown to be highly proliferative and provide 
the regenerative capacity following hepatectomy (20). Another theory is that, 
similarly to processes that can occur in cancer cells, increases in ploidy enhance the 
functionality of these cells due to increased gene copy numbers and resistance to 
harmful mutations. Although it has been shown that polyploid hepatocytes display 
deviation from diploid counterparts in gene expression, genomic resilience would be 
of benefit to hepatocytes as  processes of detoxification requires frequent exposure 
to mutagens, such as alcohol and certain carcinogenic catabolytes (21, 22). 
Interestingly, as with other cases of polyploidy, hepatocytes also undergo reductions 
in ploidy (23, 24). This gives the rise of the idea, coined by Duncan et al, 2010, of the 
ploidy conveyor model, whereby hepatocytes cycle through different stages of ploidy 
(Figure 2B) (23). Overall, changes in ploidy may act as a form of adaptation within 
the liver, in response to liver damage, in similar manner as how polyploidisation is a 
process under the influence of Darwinian selection. Taken together, it seems that 
hepatocytes are highly adaptable cells and utilise polyploidisation as a method of 
withstanding the harsh conditions of the liver. Of interest, although hepatocyte 
polyploidisation bares resemblance to that of cancer cells, they do not share similar 
phenotypes. Furthermore, sporadic hepatocellular carcinoma occurs in less than 4% 











Figure 2: The dynamics of ploidy alterations in hepatocytes.  
A: Schematic depicting the changes in nucleation and multinucleation in liver cells as a 
result of alternating cycles of success and failure of cytokinesis.  
B: The ploidy conveyor model depicting the balance between changes in ploidy in 
hepatocytes. The large number of red arrows for polyploidisation and aneuploidy represents their 
dominance in the hepatocytes compared with ploidy reversal.  Both processes are influence by 
regenerative and growth signals, although the origin of initial diploid cells within the cycle is not 





1.4 Phagocytosis can also create large intracellular vacuoles and interrupt 
cytokinesis 
It has been shown that internalisation of live cells can lead to the generation of a 
large intracellular vacuole which prevents correct segregation of dividing cells 
through cytokinesis (2, 3). However, other examples of asymmetric cell division have 
been described as a consequence of phagocytosis (26). Phagocytosis of invading 
pathogens and apoptotic cells has been well described in other renowned 
phagocytes (27). The contents of such phagosomes are often trafficked through the 
endosomal pathway, where they are degraded and in some cases presented to 
lymphocytes in the context of MHC molecules to establish innate immunity (27). 
However, under certain circumstances, phagocytosis is also thought to result in a 
persistent vacuole which can disrupt cytokinesis. It has been observed that 
multinucleated fibroblastic cells arise in rats in part due to phagocytosis of collagen 
(28). Furthermore, certain bacteria species can reside in phagosomes and disrupt 
normal cellular processes. For example, multinucleation in endocervical epithelium 
has been historically observed following infection with Tuberculosis (29).  More 
recently, asymmetric cell division was been observed as a consequence of 
Chlamydia infection (26). Chlamydia trachomatis, an obligate intracellular parasite of 
humans, persists in host cells in large inclusion bodies. These can occupy up to 20% 
of host cell volume thus create a physical obstacle. As such, it was shown that C. 
trachomatis infections can inhibit furrowing during cytokinesis in a similar manner to 
cell-in-cell structures and generate binucleate cells (Figure 3) (26). In total, this 
shows that entosis is not the only means towards non-genetic polyploidy and the 
phagocytosis can be linked to multinucleation through cytokinesis failure. 
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1.5 What are the consequences of phagocytosis for hepatocytes?  
It is of wide regard that hepatocytes are capable of phagocytosis. They have been 
historically shown to phagocytose erythrocytes (30). Additionally, they are capable of 
clearing their apoptotic neighbours, displaying another role of these cells in liver 
homeostasis(31). Finally, previous research conducted in the Stamataki lab has 
demonstrated the capability of both primary hepatocytes and hepatomas to 
phagocytose dead lymphocytes (32). However, unlike the phagocytic processes 
conducted by dedicated phagocytes, such as macrophages, the mechanisms by 
which hepatocytes take up cargo are poorly understood. Of interest, Bertolino and 
colleagues demonstrated that autoreactive CD8+ T-cells could be become activated 
in the liver and actively bore into hepatocytes through entosis, where they were 
eliminated through lysosomal degradation (33). Although such observations were not 
a consequence of phagocytosis, these studies demonstrated the existence a 
complex relationship between liver and immune cells, which may ultimately regulate 
the inflammatory response within the liver. Furthermore, this internalisation of 
autoreactive CD8+ T-cells supports the Overholtzer entosis theory of polyploidy (34). 
The consequences of both entosis and phagocytosis of lymphocytes and apoptotic 
cells by hepatocytes are under investigation (33). However, little attention has been 
given to the impact of cell-in-cell structures on the hepatocytes themselves. Studies 
suggest that multinucleation and polyploidy can arise from failed cytokinesis, as a 
result of a physical obstruction in cell cleavage (3, 24, 26). As hepatocytes are both 
phagocytic and exhibit polyploidy, there is likelihood that both processes are linked. 
This investigation will endeavour to establish the consequences of phagocytosis for 
the hepatocytes and analyse its effects on multinucleation, as a representation of 
polyploidy. These observations will be confirmed using immunohistochemical 
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Figure 3: Time-lapse, epifluorescent images of showing asymmetric cleavage furrows in 
HeLa cells infected with Chlamydia. HeLa cells expressing histone H2B-mCherry and transiently 
expressing Cerulean-LifeAct (F-actin; green) were observed with or without a Chlamydia inclusion. 
Taken from Sun et al, 2011 (26). 
Uninfected Chlamydia infected 
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1.6 Aims and Objectives 
We hypothesise that phagocytosis of dead cells has consequences for hepatocyte 
ploidy. This investigation aims to identify the outcomes of hepatocyte phagocytosis 
and elucidate its effect on multinucleation. Such experiments will be conducting 
using Huh-7 hepatoma cell lines as a representative model for convenience. 
However, these cells are less differentiated and polarised than primary hepatocytes. 
As such, findings from these initial experiments will be supported with data obtained 
from primary hepatocyte experiments and with in vivo analysis of liver segments. We 
designed objectives to answer the following questions: 
 Does phagocytosis of heat-killed cells affect cell division and multinucleation 
in hepatomas? 
 Can primary hepatocytes phagocytose heat-killed cells? 
 Can entosis or phagocytosis be observed and distinguished in liver sections 








2 MATERIALS AND METHODS 
2.1 Antibodies 
Table 1: List of antibodies used throughout this investigation including their 
source and purpose 
 
2.2 Reagents 
Table 2: List of reagents and chemicals used throughout this investigation 
including their source and purpose 
Reagent Source Purpose 
Dulbeccos modified eagles 
medium (DMEM), high 




Cell culture – Huh-7 
growth medium 
Iscove’s Modified 
Dulbecco’s Medium, + 





Cell culture – Huh-7 
growth medium following 
phagocytosis 
Antibody Source Purpose Concentration 
Mouse anti-CD3 abcam® (ab699) Immunohistochemistry 
















Roswell Park Memorial 
Institute Medium 1640, 










Cell culture – detachment 
of cells from culture flask 




Cell culture – Media 
supplement 
100X MEM Non-essential 
















Cell culture – Media 
supplement 
Williams E Medium 
GIBCO/Invitrogen™ 
(32551-020) 
Cell culture – Primary 






Cell culture – Primary 
hepatocyte growth media 
supplement 
CellMask™ Orange 
Molecular Probes, Life 
Technologies™ (C10045) 
Assessing multinucleation 





Molecular Probes, Life 
Technologies™ (H3570) 
Assessing multinucleation 




Reduced serum media for 





Transfection of Huh-7 with 
exogenous fluorescent 
cytoskeletal elements 
CellTracker™ red CMTPX 
Molecular Probes, Life 
Technologies™ (C10613) 
Fluorescent labelling of 






Molecular Probes, Life 
Technologies™ (C2925) 





Fixing of phagocytosis 
primary cells 
Tumour Necrosis Factorα 
(TNFα) 
PeproTech™ (300-01A) 
Analysing the effects of 
cytokines for PHH 
phagocytosis 
Interferon-γ (IFNγ) PeproTech™ (AF-315-05) 
Analysing the effects of 
cytokines for PHH 
phagocytosis 
Unmasking solution – High 
pH 
Vector® (H3300) ISEL/Immunohistochemisty 
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Unmasking solution – Low 
pH 
Vector® (H3301) ISEL/Immunohistochemisty 
Peroxidase-Blocking 
Solution 




10X Casein Solution Vector® (SP-5020) Immunohistochemisty 





– tissue rehydration and 
dehydration 
Industrial Denatured 





– tissue rehydration and 
dehydration 
EnVision FLEX wash 
buffer (Tris-buffered saline 




























peroxidase substrate kit substrate/detection 
Sheep anti-digoxigenin 
alkaline phosphatase 
conjugated F’ab fragment 
Roche (1093274) ISEL 
StayRed/AP substrate 
(alkaline phosphatase) 







StayGreen/AP substrate abcam® (ab156428) ISEL detection 
100% Ethanol (EtOh) 
Sigma-Aldrich™ (E7023-
500ML) 
Sterilisation and tissue 






Tissue dehydration for 
ISEL/IHC double stain 
VectaMount AQ Aqueous 
Mounting Medium 
Vector ® (H-5501) 
Immunohistochemisty-
mountant 











2.3 Cell Culture 
All cell culture procedures were conducted within Laminar class II flow cabinets 
(Thermo Scientific Holten, Safe MS). Cabinets were sterilised before and after use 
by treatment with 10% Trigene solution, followed by 70% EtOh.  All cells were 
cultured in 5% C02, at 37°C. 
2.4 Cell Lines 
2.4.1 Huh-7 Hepatoma cells 
Huh-7 cells were cultured in T75cm2 culture flasks in DMEM containing 10% Foetal 
Bovine Serum (FBS), 1% NEAA, 1% Pen/Strep, 1% L-glutamine. Cells were allowed 
to grow until reaching 100% confluence, which was assessed through light 
microscopy. At this stage, media was removed and cells were washed with 10 
Phosphate Buffer Solution (PBS). 2.5ml 0.05% trypsin-EDTA was added to cultures, 
ensuring an even coverage, and flasks were incubated at for 4min 37°C, 5% C02 to 
allow trypsin to take effect. Cultures were agitated and then analysed by light 
microscopy to ensure that all cells had detached. Trypsing-EDTA was then 
quenched with the addition of 2.5ml DMEM. Media-Trypsin-solution was drawn up 
with an electronic pipette and released down the culture plane of the flask to ensure 
that all cells were collected in a pool at the bottom of the flask. 1ml was removed 
from these cultures and added to a new flask with 9ml DMEM with all supplements. 
Remaining cells were seeded elsewhere, heat-killed for phagocytosis experiments or 
discarded. Huh-7s were propagated twice per week in this fashion to ensure that 
cells remained healthy and did not overgrow.  
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2.4.2 Jurkat T-cell lymphoma cells 
Jurkat cells were cultured in 20ml RPMI containing glutamine, supplemented with 
10% FBS, 1% NEAA and 1% Pen/Strep. Cells were allowed to grow until solutions 
appeared cloudy and lost their phenol red colour. At this point, to ensure that cells 
remained healthy, 12ml of Jurkat suspension was removed with an electronic and 
discarded. Suspensions were then topped-up back to 20ml with supplemented 
RPMI. Jurkat cells were propagated twice per week in this fashion, unless they were 
used for experiments.  
2.4.3 Primary Human Hepatocytes (PHHs) 
Liver tissue was obtained from surgical procedures carried out at the Queen 
Elizabeth Hospital, Birmingham, UK. Ethical approval for the study was granted by 
the Local Research Ethics Committee (LREC) (reference number 
06/Q702/61). Primary hepatocytes were isolated by Dr Elizabeth Humphreys. Liver 
tissue was obtained from fully informed and consented patients undergoing 
transplantation for a variety of end stage liver diseases or from normal donor tissue 
that was surplus to surgical requirements. 
 
Hepatocyte isolations were carried out using a modified ‘two-stage’ collagenase 
procedure developed by Berry and Friend and further modified by Bhogal et al 2011 
(35, 36). The cells were seeded at 80% confluence (1.04x105 cells) on a rat tail 
collagen-coated 48-well plate in arginine-free Williams E media supplemented with 
10% fetal calf serum, hydrocortisone (2ug/ml), insulin (0.124U/ml) and L-ornithine 
(0.4mmol/L). Cells were cultured for 2 hours under normal conditions to ensure that 
the cells adhered to the bottom of the wells and were then switched to serum-free 
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Williams E media with supplements for 24 hours. The cells were then subjected to 
phagocytosis assays and were not propagated further.   
2.5 Heat-killing 
Phagocytosis assays were carried out using cell lines which had been killed with 
heat. Heat-killing was conducted with Huh-7s from a confluent flask and with Jurkat 
suspensions that had been allowed to grow for 3 days after being passaged. Prior to 
heat killing, Huh-7s underwent normal detachment procedures and transferred to a 
centrifugable tube. Jurkat cells were also transferred to a centrifugable tube. Cells 
were centrifuged for 3min, 1500rpm at room temperature. Supernatents were 
discarded and cell pellets were resuspended in 1ml of their respective culture media 
and transferred to a 1.5ml tube. Cells were then killed at 60°C on a heating-block for 
30mins. Cells were given time to cool before they were added to live cell cultures.  
2.6 Creation of de novo Huh-7 cell lines by phagocytosis  
In order to assess in the effect of phagocytosis on Huh-7 multinucleation, novel Huh-
7 cell lines were created by inducing phagocytosis. Huh-7s were detached through 
normal procedures and in new T25cm2 culture flasks at 50% confluence (1.5x106) 
and allowed >8hours to adhere in 5ml media. Heat-killed Huh-7 cells or Jurkats were 
then added to cultures and were incubated under normal conditions. A control 
culture was also set which did not receive dead-cells but underwent the same 
treatments as phagocytosing cells. Phase contrast images of cultures at 20x 
magnification were taken throughout and proceeding phagocytosis using a Nikon 
Eclipse TE2000-S inverted microscope. The media was changed for each culture 
after 3 days,or if the culture media appeared a bright yellow colour, to remove non-
phagocytosed cells remove harmful products released by heat-killed cells. Cells 
were allowed to continue phagocytosis until cultures became confluent or finished 
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phagocytosis. Cells were then detached by normal trypsin treatment. In this case, 
trypsin was quenched with IMDM containing 10% human serum, 1% NEAA and 1% 
Pen/Strep. Cells were then seeded in T75cm2 flasks and cultured in IMDM until 
normal cell division patterns were restored. Cultures were then returned to normal 
DMEM conditions and from here on treated as in individual cell line, based on the 
cells they had phagocytosed and how many events of phagocytosis they had 
undergone (Huh-7/Jurkat feed 1, feed 2 etc). All events were then repeated with 
“feed 1 cells” and then again with “feed 2” giving a total of three feeding events.  
2.7 Multinucleation Assays 
All fluorescence imaging for this assay was conducted using the Nikon Eclipse 
TE2000-S inverted microscope. In order to assess multinucleation in new 
phagocytosis-derived Huh-7 cell lines, cells for each feed (including unfed controls) 
were seeded in 24-well-plates at 50% confluence (0.12x106 per well) and allowed to 
adhere for >8hours in 1ml supplemented DMEM. Nuclei were stained with 0.2µg/ml 
Hoechst dye in 1ml normal DMEM for 30min, at 37°C. The stain was removed and 
cells were briefly washed in 1ml PBS PBS before normal DMEM was replaced. Cells 
were briefly imaged to ensure that blue nuclei were visable. To distinguish individual 
cells in culture, cell membranes were stained with 5µg/ml CellMask Orange in 1ml 
DMEM for 5min, 37°C. Wells were then washed briefly in 1ml PBS and 1ml DMEM 
was added to each well before imaging. 10 fields of view at 20x magnification were 
analysed for each cell line. For each field of view, the total number of cells and the 
total number of multinucleate cells were counted. From this data, the average 
percentage of multinucleate cells was determined for each cell line. All data was 
plotted in Microsoft Excel and the highest and lowest percentages of multinucleation 
for each cell line were used for error bars.  
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2.8 Assessment of phagocytosis in primary human hepatocytes 
All fluorescence imaging for this assay was conducted using the Nikon Eclipse 
TE2000-S inverted microscope. Once PHHs had adhered to collagen-coated wells, 
they were assessed for their ability to conduct phagocytosis. The original media was 
removed and PHHs were stained green with 5µM CellTracker CMFDA in 300µl 
DMEM, containing normal culture supplements, for 1 hour, 37°C in the dark. Wells 
were then washed in 500µl PBS and replenished with 500µl normal DMEM. PHHs 
were briefly analysed to ensure that the green stain was successful. 4 wells received 
media contained 100ng/ml TNFα, IFNγ or both. All cells were incubated for 1hour, 
37°C, C02 before receiving heat-killed cells. Jurkat cells were stained with CMTPX 
and heat-killed as previously done (section 2.7). 100µl red, heat-killed Jurkats were 
added to each well and PHHs were allowed to conduct phagocytosis for 2 hours at 
37°C, 5% C02. Following this, cells were fixed with 1% PFA in PBS for 5min, 37°C. 
The fixative was removed and 300µl PBS was added to ensure cells did not become 
dehydrated. Images of green PHHs, red Jurkats and merged were taken of 10 fields 
of view for each cytokine treatment, including untreated. These images were then 
analysed to assess the percentage of phagocytosing PHHs and the average number 
of Jurkats internalised per Huh-7. Jurkats were identified as internalised if their 
position correlated with the presence of a vacuole within Huh-7s. Tallies were made 
for cells possessing up to 6 internalised Jurkats. Data representing the mean 
percentage of phagocytic cells were analysed and plotted with Microsoft Excel. Data 
representing the mean number of internalised Jurkat cells were analysed and plotted 




All data for Huh-7 multinucleation and primary human hepatocytes were statistically 
analysed using paired t-tests using Prism (GraphPad) software. Statistical 
significance in multinucleation changes was determined between unfed and feed 3 
cell lines. Statistical significance was also assessed for increases in the percentage 
of phagocytosing PHHs due to cytokine treatments.  
2.10 Immunohistochemistry (IHC) 
2.10.1 Paraffin liver Sections from diseased livers 
All sections were cut from liver tissue, obtained from surgical procedures carried out 
at the Queen Elizabeth Hospital, Birmingham, UK. Ethical approval for the study was 
granted by the Local Research Ethics Committee (LREC) (reference number 
06/Q702/61). All tissues were fixed in formulin and embedded in paraffin wax. 3µm 
deep sections were then cut using a rotary microtome sections and then floated 
within a water bath to remove undesired tissue folding. Tissue sections were then 
mounted onto charged glass slides. Sections were then loaded into a metal rack and 
set by incubated at 60°C.  Tissue sections came from patients suffering with chronic 
rejection, alcoholic liver disease, primary biliary cirrhosis and primary sclerosing 
cholangitis.   
2.10.2 Anti-CD4 and CD3 staining 
All IHC procedures were conducted at room temperature. All washes and were 
conducted in glass staining dishes or Coplin jars. Paraffin tissue sections were 
placed in a metal rack and rehydrated at room temperature within a fume hood, 
using the following treatment series: 3 x 2 min incubations in xylene, 2 x 2 min 
incubations in IDA and left in ddH20 in order to wash off excess alcohol and keep 
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tissue sections hydrated. 1L, 0.1% high-pH unmasking solution (2X overall) was 
prepared and preheated in a microwave oven for 10 mins. Rehydrated tissue 
sections were submerged in pre-warmed unmasking solution and microwaved on the 
highest setting for a further 20min. Sections were allowed to cool for 10min following 
microwave proteolysis. Plastic staining trays were lined with damp paper towels, to 
ensure the atmosphere remains moist, and broken glass stripettes were placed 
parallel inside. Excess unmasking fluid was removed from tissues sections and they 
were washed in EnVision FLEX wash buffer (TBST from here on) for 5min and they 
were placed level on stripettes within the staining tray. The lid was replaced on the 
tray during all incubations. 100µl peroxidase-blocking solution was added to each 
section for 10min and then washed with 2x5 min washes in TBST. A working casein 
blocking solution was made by dilution 1ml 10X stock in 4ml TBST. 100µl of working 
casein block was added to each section for 10min. Tissues were then incubated with 
100µl of anti-CD4 or anti-CD3 primary antibody in TBST at concentrations depicted 
by Table 1, for 1 hour at room temperature. Sections were then washed 2x5mins in 
TBST and then incubated with Vector ImmPRESS universal antibody polymer 
detection kit for 30min, according to the manufacturers guidelines. Sections were 
then washed 3 times in TBST and then suspended on staining rack over a sink. 
Sections were stained with Vector immPACT DAB peroxidase substrate using a 
Pasteur pipette for 5min, according to the manufacturer’s guidelines. DAB was 
removed by drowning slides in distilled water. Mayers haemotoxylin was filtered 
twice using filter paper and a funnel prior to use. Tissues were counterstained for 
30sec and the stain was developed by running slides under hot water. Tissue 
sections were then dehydrated by the following treatment series: 2 x 2 min 
incubations in IDA, followed by 2x2 min incubation in xylene.  Tissue sections were 
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then mounted by adding one drop of DPX mounting media to a coverslip and 
carefully pressing the section on to the coverslip to ensure that no bubbles form. 
Slides were then imaged once the mountant had dried.  
2.10.3Anti-HNF4α 
HNF4α IHC staining was conducted following procedures outlined by Tanaka et al, 
2006 (37). However, antigen unmasking procedures were not outlined by the author. 
As such, 3 methods of unmasking were conducted: high-pH, low-pH and no 
unmasking prior to initial washing in TBST. Following casein blocking, tissue 
segments were incubated with 100µl K9218 anti-HNF4 primary antibody (1:100) in 
1% BSA/PBS (final concentration 10µg/ml) overnight at 4°C in the dark. All other 
procedures were identical to those of section 2.9.2. 
2.11 In Situ End Labelling (ISEL) 
ISEL staining was conducted for both paraffin embedded sections and frozen Jurkat 
cytospins which were already available in the lab. Jurkats had been cultured in 
normal RPMI or RPMI containing FasL. These cells were used as a control for the 
detection of apoptosis by ISEL. Paraffin sections underwent rehydration and epitope 
unmasking, as described in section 2.9.2. To optimise epitope unmasking and 
minimise non-specific staining, paraffin sections were microwaved for 20, 30 or 
40min. During this time, frozen sections were re-fixed in acetone for 2min and 
allowed to air-dry. Plastic staining trays were lined with damp paper towels, to 
ensure the atmosphere remains moist, and broken glass stripettes were placed 
parallel inside. Finally, the ISEL mixture was prepared according on ice to table 4. 
Once frozen sections had dried and paraffin sections had cooled, wax was applied 
around each tissue section or cytospin to ensure that the mixture was retained. 
Sections were incubated with 100µl ISEL mixture, or negative control mixture where 
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the Klenow fragment was withheld, under glass coverslips for 1 hour, 37°C. 
Following this, coverslips were removed and slides were washed 3x 5 minutes in 
ddH20, followed by then 5 minutes in TBS pH 7.2. Both cytospins and tissue sections 
were then incubated in 100µl, 3.75U/ml sheep anti-digoxigenin alkaline phosphatase 
conjugated F’ab fragment, diluted in TBS pH 7.2 for 1 hour at room temperature 
within the staining tray. Slides were then washed in TBS pH7.2 for 5min and then 
visualised by incubating with abcam StayRed/AP substrate for 15min. Slides were 
then washed in ddH20 and counterstain with haematoxylin as previously stated 
(Section 2.9.2). Cytospins were mounted in VectaMOUNT aqueous mountant. 
Paraffin sections were dehydrated and mounted in DPX mountant as described 
(Section 2.9.2). 
Component Concentration Source 
MgCl2 0.005M Sigma Aldrich™, (M8266) 
Β-mercaptoethanol 0.001M Sigma Aldrich™, (3148) 
Bovine Serum Albumin 
(BSA) 















 DNA polymerase, Klenow 
Fragment 
20U 
Bioline™, Taunton MA 
USA, (BIO-27029) 
TBS pH 7.2 






2.12 ISEL and Anti-CD3+ IHC double stain 
The processes of both anti-CD3 staining and ISEL treatment of paraffin sections 
were combined in the following sequence. All washes and were conducted in glass 
staining dishes or Coplin jars. Paraffin sections underwent rehydration, epitope 
unmasking and 20min microwaving, as described in section 2.9.2. Following this, 
sections were washed in TBST for 5min and then incubate with peroxidase-blocking 
solution for 10min at room temperature. Slides were washed in TBST for 5min and 
then again in TBS for another 5min. Following this all ISEL procedures were 
conducted as describe in section 2.11, starting from the incubation with the ISEL 
mixture. For this technique, ISEL visualise was conducted using StayGreen/AP 
substrate. As this is light sensitive, sections were incubated with StayGreen/AP 
substrate for 30min in the dark at room temperature. Slides were washed in ddH20 
for 5min and then again in TBST for another 5min. IHC procedures detailed in 
section 2.9.2 were the conducted, beginning with casein block. Anti-CD3 was used 
at 1:100 dilution in TBST. IHC staining was visualised using Vector imPACT Novared 
peroxidase substrate according to the manufacturer’s guidelines. This reaction was 
stopped by drowning slides in distilled water. Sections were counterstained with 
haematoxylin and then dehydrated using the following series, conducted in Coplin 
jars: 2x30sec in 100% ethanol, >30 sec in clearine. This series was done to ensure 
Table 3: Components of the in situ end-labelling mixture  
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that the Novared substrate did not leach. Slides were mounted using one drop of 
vectaMOUNT agueous mountant.  
2.13 Tissue Section Microscopy 
All stained tissue sections were imaged at 20x magnification using a Zeiss Axioskop 
40 microscope. Representative images were taken for each slide and scale bars 


















3.1 Phagocytosis alters cell division and promotes multinucleation in human 
hepatomas 
The generation of cell-in-cell structures through processes such as phagocytosis or 
entosis can have profound effects on cellular ploidy (1). Previous investigations in 
the Stamataki lab had shown that Huh-7 hepatoma cell lines are capable of 
phagocytosing heat-killed lymphocytes and cell lines, as well as their own kind. 
Interestingly, these cells do not undergo cell division whilst conducting phagocytosis.  
We endeavoured to characterise the consequences of this extended period of 
phagocytosis for the hepatocyte. Huh-7 cells were “fed” heat-killed Huh-7 or Jurkat 
lymphoma cell lines. Dead Huh-7 are larger than lymphomas and therefore large 
phagosomes may cause more mechanical disruption to cell division, yet dead 
lymphocytes are smaller and multiple cells can be phagocytosed at the same time.  
A control unfed culture of Huh-7 was set up for comparison. Unfed cultures divided 
as normal and were passaged as required.  Phagocytosing cultures underwent 
minimal cycles of cell division throughout this period (1 week approximately). Figure 
1A shows differences in Huh-7 morphology acquired after phagocytosis of heat-killed 
lymphomas or hepatomas.   
To quantify the effects of sequential phagocytosis in hepatoma cell division, cultures 
were fed more cells or propagated. Cell lines were generated for up to three 
consecutive cycles of phagocytosis were generated of both Huh-7 and lymphoma 
phagocytosis Of great surprise and interest, Huh7s that underwent a third round of 
lymphoma phagocytosis appeared to undergo processes of differentiation (Figure 
1B). Such cultures did not reach confluency even after one month after the 
completion of phagocytosis, and only required media changes. These cells 
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conducted 10-times fewer divisions than normal unfed cells (Figure 1C). Additionally, 
the culture appeared to become heterogeneous (Figure 1B);smaller box-like cells 
were present which resembled polarised primary hepatocytes and formed tight 
layers with each cells (differentiated cell type I), as well as larger cells, some of 
which were multinucleate (differentiated cell type II). Such a difference in phenotype 
may be the result of asymmetric cell division giving rise to 2 distinct cell lines. Our 
findings raise questions as to how phagocytosis of dead cells can lead to potential 
differentiation events.  
In order to assess changes in multinucleation during phagocytosis, the percentage of 
multinucleate cells in 5 fields of view at x20 magnification was estimated for each cell 
line. Nuclei and cell membranes were stained with Hoechst dye and CellMask 
membrane dye, respectively, to assist the identification of single cells (Figure 1D). 
Multinucleation gradually increased in unfed culture propagated over 3 weeks. This 
is likely due to background phagocytosis of none-adherent cells within the culture. 
However, phagocytosis of both Huh-7 and lymphoma cells caused significant 
increase in multinucleation (Figure 1D). In particular, phagocytosis of lymphomas 
caused a 4% increase between the 1st and 2nd feeds and an even larger increase of 
10% between the 2nd and 3rd. This suggests that the ability of these cells to 
phagocytose lymphomas is cumulative. Phagocytosis of dead Huh-7 cells also 
caused a 5% in multinucleation, compared to unfed cells. However, the increase 
been feeds 1 and 2 was minimal. This may be in part due to the larger size of Huh-
7s compared to lymphomas or be due to molecular challenges. As such, the data for 
feed 3 was not obtained as the cells failed to adhere to the flask at passaging. 
Overall, these data show that prolonged phagocytosis has profound effects on cell 




Figure 4: Phagocytosis of heat-killed Huh-7 and lymphomas has profound effects on Huh-7 ploidy. A: Light 
micrographs of phagocytosing Huh-7 cultures. Cultures were incubated heat-killed Huh-7s or lymphoma cell 
lines until cells ceased to phagocytose or until cultures became confluent. Media was changed once all cells were 
phagocytosis minimalise toixins released from heat-killed cells. B: Light micrographs of normal Huh-7s and the 
heterogeneous culture generated following 3 round of lymphoma phagocytosis. C: The number of cell 
divisions undertaken by normal, unfed Huh-7 cells and lymphoma –fed Huh-7s undertaking their third 
round of phagocytosis. D: Bar chart displaying changes in Huh-7 multinucleation following consecutive 
rounds of phagocytosis. The percentage of multinucleate cells was assessed after each feed for each type of 
cargo. Nuclei were stained with Hoechst and cell membranes were stained with CellMask™ orange in order to 
distinguish between individual cells. Error bars represent highest and lowest percentage of multinucleate cells. 
P<0.05 
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3.2 Primary hepatocytes are capable of phagocytosis and cytokine stimulation 
increases the quantity of internalised cells  
Experiments conducted in the early stages of the investigation were done using 
Huh7 cells. This is an established cell line which is convenient and easy to use as a 
representative of hepatocytes. However, as such cells are immortalised hepatomas, 
they do not share the same physiological characteristics. Huh7s do not polarise like 
hepatocytes and share common features of other immortalised cells. As such, it was 
not possible to assume that the observed effects would occur in vivo. To address 
this, primary hepatocytes were generously isolated and provided by Dr. Elizabeth 
Humphries. These cells were stained with CellTracker green CMFDA and then co-
cultured for 2 hours with heat-killed Jurkat cells, which had been stained with 
CellTracker red CMTPX. As cytokine activation is known to increase phagocytosis 
rates in hepatomas (Nick Weight et al, manuscript in preparation), some cells were 
treated with TNFα, IFNγ or both prior to incubation with jurkats. Cells were washed, 
fixed in 1% (w/v) paraformaldehyde, and then imaged using a fluorescent 
microscope. Merged fluorescent images of 10 fields of view were taken for each 
cytokine treatment and the total frequency of internalisation, together with number of 
Jurkats internalised by each hepatocyte was estimated (Figure 5).  
Internalised Jurkat cells appeared as black vacuoles within green hepatocyte 
cytoplasm that corresponded to the positions of red cells (Figure 5A). Hepatocytes 
conducted phagocytosis of Jurkat cells under all conditions, showing that primary 
hepatocytes are capable of phagocytosis. Furthermore, prior treatment of 
hepatocytes with TNFα or IFNγ increased the total level of phagocytosis within these 
cells and increased the average number of Jurkats internalised per cell (Figure 
5B/C). Interestingly, IFNγ induced a greater amplification of phagocytosis. This 
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suggests that IFNγ may be a more potent activator of phagocytosis and that each 
cytokine may upregulate phagocytosis through distinct mechanisms. In support of 
this, treatment with both cytokines elicited a significant increase in phagocytosis than 
either single treatment (P<0.05). This is consistent with our data on cytokine 
modulation of phagocytosis in Huh-7 cells (32). In total these results show that 
primary hepatocytes naturally perform phagocytosis of dead cells, a behaviour which 




















Figure 5: Primary hepatocytes internalise heat-killed Jurkat cells and this is enhanced with inflammatory 
cytokine treatment: Jurkat cells were dyed red with CellTracker CMPTX prior to heat-killing treatment. Primary 
hepatocytes were extracted from a donated liver and seeded in 48-well plates at 80% confluence, courtesy of Dr. 
Elizabeth Humphreys. Hepatocytes were stained green with CellTracker CMFDA and then treated with 
inflammatory cytokines for 1 hour. Cytokines were washed off and hepatocytes were incubated with heat-killed 
Jurkat cells for 2 hours. All cells were then fixed with 1% paraformaldehyde in PBS for 5 mins and stored at 4°C 
in PBS. Ten fluorescent images were then taken of fixed cells for each cytokine treatment. A: Fluorescent 
micrographs of phagocytosing primary hepatocytes. Jurkats were determined as ‘internalised’ where the 
appearance of vacuoles within green hepatocytes cytoplasm corresponded to the appearance of red Jurkat cells. 
B Bar chart showing the percentage of hepatocytes with internalised cells following cytokine treatment.  
P<0.05 C Dot plot showing the number of cells internalised by each phagocytosing hepatocyte following 







3.3 Can we measure hepatocyte internalisation of live and dead T-cells in 
inflammation in vivo? 
3.3.1 Immunohistochemistry can be used to identify T-cells in diseased livers 
To study entosis and phagocytosis of CD4+ T cells in vivo, we made use of the liver 
tissue bank of formalin-fixed paraffin embedded tissue sections and set out to 
optimise immunohistochemistry (IHC) staining for CD4. We first conducted anti-CD4 
IHC staining of livers from patients with alcoholic liver disease (ALD) and primary 
biliary cirrhosis (PBC), in order to identify T-cells. These diseases were selected as 
they are each known to have ample T cell infiltrates during inflammatory responses 
(39). Antibodies were used at 1:10, 1:20 and 1:40 dilutions in order to optimise the 
protocol. Staining for these sections was weak or non-specific for all concentrations 
used, therefore unsuitable for identifying T cells inside hepatocytes (Figure 6). 
Following this, we tested anti-CD3 staining. For concentrations above and including 
1:100, we visualised small cells which were positively stained, scattered throughout 
each tissue section (Figure 6). Furthermore, aggregates of lymphocytes were seen 
around portal areas and around fibrotic. As such, these proceedings demonstrated 
that IHC could be used to identify lymphocytes in vivo using an anti-CD3 antibody.   
3.3.2 In Situ End-Labelling (ISEL) can be used to detect apoptotic cells in vivo 
without proteolytic treatment 
Although we had established a method for visualising lymphocytes within the liver, it 
was not yet a possibility to determine the viability of these cells. Although it was 
possible to visualise lymphocytes that had been engulfed by hepatocytes, 
differentiating between entosis of live cells, or phagocytosis of apoptotic cells 
remained a challenge. A staining technique for the visualising apoptotic cells had 
been established called In-Situ End Labelling (ISEL). This technique uses Klenow 
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fragment to add labelled nucleotides to free 3’OH groups in DNA, created as a result 
of apoptosis-induced endonuclease activity. This technique had also been optimised 
for accurate visualisation without the need for enzymatic proteolytic treatment, 
instead using pressure cooker and citrate buffer solution to unmask epitopes (40). 
We are now no longer able to use pressure cookers in our laboratories so we had to 
test treating tissue sections with microwave heat instead.  To see if this technique 
could be used to identify apoptotic cells within paraffin liver sections, ISEL was 
performed for chronic rejection liver sections. The Klenow fragment was left out for 
some sections in to ensure that stain was specific to its activity. To optimise the 
unmasking pretreatment, sections were microwaved for 20, 30 or 40 minutes to 
identify the time which resulted in a more accurate stain. The technique was also 
performed on frozen Jurkat cell cytospins, some of which had been treated with FasL 
to induce apoptosis. Both Jurkats and liver sections which did not receive Klenow 
fragments only showed haematoxylin counterstaining (Figure 7). This shows that any 
signal observed from ISEL staining was as a result of the Klenow fragment. 
Furthermore, all Jurkats that were pre-treated with FasL were positive for ISEL 
staining, displaying the accuracy of this technique to identify apoptotic cells. 
Additionally, hepatocytes were ISEL stained successfully for all microwave times for 
chronic rejection tissues, which are rich in apoptotic cells. Sections undergoing a 
20min proteolysis showed prominent nuclear staining, and lower non-specific 
cytoplasmic staining and blotching in comparison to longer times. This is probably 
because prolonged microwaving times can damage epitopes. This investigation thus 
shows that apoptotic cells can be accurately identified within paraffin liver sections 
using microwave treatment for epitope unmasking.  
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3.3.3 ISEL and Immunostaining can be conducted together to identify both T-
cells and apoptosis 
We had so far confirmed that it was possible to identify lymphocytes in liver sections 
using immunohistochemistry and that it was also possible to identify apoptotic cells 
with ISEL. The challenge that remained was to develop a protocol which utilised both 
techniques, which had not been attempted before. To this end, a protocol was 
devised, whereby tissue sections would initially undergo peroxidase blocking, 
followed by ISEL and then anti-CD3 IHC staining. We chose a red alkaline 
phosphatase substrate for ISEL and a green peroxidase substrate for CD3 in order 
to obtain a greater contrast between the two stains. As lymphocytes have large 
nuclei encapsulated in a small layer of cytoplasm, we would expect to see large red 
nuclei, with a “halo” of green representing the cytoplasm. Staining was performed on 
chronic rejection and alcoholic liver disease sections, as these had proved 
successful for the previous single stains. Several red cells were seen for both tissue 
sections, indicating that the ISEL was successful and could be visualised with this 
red substrate (Figure 8). Unfortunately, the green peroxidase substrate used to 
visualise anti-CD3 in the combined stained protocol was too bright, non-specifically 
staining all cell nuclei. Careful titration of the detection reagents is needed to 





3.3.4 Internalised cells and hepatocyte nuclei can be distinguished using anti-
HNF4 IHC 
We had established that it was possible to identify lymphocytes within paraffin 
sections and simultaneously determine if they are apoptotic through double staining. 
Such a technique can be used to identify phagocytosed cells. However, these cells 
are of a similar size and appearance to hepatocyte nuclei. Furthermore, many 
hepatocytes are apoptotic within diseased tissues and may provide difficulty when 
identifying double-stained cells. Finally, as hepatocytes are commonly multinucleate, 
the appearance of 2 spherical bodies within a hepatocyte does not guarantee that 
one is the result of heterotypic internalisation.  Staining hepatocyte nuclei specifically 
instead of targeting lymphocytes may overcome this problem. Hepatocyte nuclei 
exclusively express hepatocyte nuclear factor 4 (HNF4). This could be targeted 
using IHC to outline hepatocyte nuclei. To this end, primary sclerosing cholangitis 
(PSC) sections were subjected to anti-HNF4α IHC using a previously described 
protocol (37). As the unmasking procedures had not been outlined from this study, 
we tested 3 techniques, using high pH unmasking buffer as previously used, low pH 
solution of none at all (Figure 9). All stains conducted using low pH buffer or no 
buffer yield none-specific cytoplasmic staining. However, High-pH unmasked 
sections showed strong, specific nuclear staining in hepatocytes. Of great 
importance, biliary epithelial cells were not stained, which emphasises the specificity 
of this antibody. In total, this technique could be used to highlight hepatocyte nuclei 
















Figure 6: Anti-CD4 and CD3 immunohistochemistry (IHC) of diseased liver sections. Epitopes of 
paraffin-embedded liver sections were unmasked with high pH citrate buffer and underwent 20min 
microwave proteolysis prior to staining. Sections were then blocked with peroxidase blocking reagent 
and 2% casein solution. Sections were incubated with primary antibodies for 1 hour at room temperature. 
Positive staining was visualised using ImmPRESS HRP universal antibody (Vector) and 
Diaminobenzidene (DAB) peroxidase substrate. ALD; Alcoholic Liver Disease. PBC; Primary Biliary 






















Figure 7: Assessment of In Situ End-Labelling (ISEL) for the detection apoptotic cells in chronic rejection liver 
sections and frozen Jurkat cell cytospins. Jurkats were cultured in normal media or media containing FasL prior 
to cytospinning. FasL treated Jurkats were stained as a positive control for the detection of apoptosis. Epitopes 
on paraffin liver sections were unmasked using high pH citrate buffer and 20, 30 or 40min microwave proteolysis 
prior to ISEL staining. A control stain was conducted without the Klenow fragment to ensure that the enzyme was 
actively labeeling free-DNA end. Positive staining was visualised using ImmPRESS HRP universal antibody (Vector)  



























Figure 8: Double staining of diseased liver sections combining αCD3 IHC and ISEL. Epitopes were 
unmasked with high pH buffer and 20min microwave proteolysis. ISEL stains were performed first, following 
peroxidase blocking of paraffin sections, and visualised with StayGreen/AP substrate. Following this, liver sections 
were blocked with 2% casein solution and then inucabated with anti-CD3 monoclonal antibody for 1 hour.  using 
NovaRed™ peroxidase substrate in order to assess the new substrate and observation any effect of ISEL 






















Figure 9: Anti-Hepatocyte nuclear factor 4α (HNF4α) IHC of primary sclerosing cholangitis (PSC) paraffin 
liver sections. Sections were pre-treated with high pH buffer, low pH buffer or no buffer, and were incubated with 
αHNFα primary antibody in 1% BSA solution, overnight at 4°C. Positive staining was visualised using ImmPRESS 





4.1 Phagocytosis in hepatocytes derivative cells causes accumulation of 
nuclei and promotes differentiation  
It has been shown in recent years that tumours cells can engulf live cells of the same 
lineage through the process of entosis (2, 3). This generation of cell-in-cell bodies 
results in polyploidisation, through cytokinetic failure and multinucleation. In addition, 
specific phagocytotic processes have also been shown to create large intracellular 
vacuoles which pose physical obstacles for cell division(41, 42). Hepatocytes have 
been shown to conduct both entosis and phagocytosis, although the outcome of this 
on hepatocyte ploidy had not been investigated (31, 33). As such, we set out to 
determine if phagocytosis by hepatocytes results in multinucleation and to establish 
if such activities could be observed in vivo. We found that prolonged, consecutive 
phases of phagocytosis by Huh7 hepatoma cells induced a cumulative increase in 
multinucleation amongst these cells. Furthermore, we made the exciting observation 
that phagocytosis induced these established proliferative cell lines to cease division 
and differentiate into cells which resemble primary hepatocytes. Of significance we 
also established that primary hepatocytes were also capable of phagocytosing heat-
killed cells, suggesting that prior observations in Huh7 cells were applicable for cells 
within the liver. Furthermore, immunohistochemistry and ISEL procedures using 
paraffin liver sections were established for simultaneous visualisation of apoptotic 
cells and lymphocytes in vivo. The observations made throughout these proceedings 
raise several questions as to the significance of polyploidy within the liver and pave 
the way for subsequent investigations into the physiological significance of 




4.2 The physiological purpose of in vivo phagocytosis in the liver 
This investigation has shown, together with other evidence from the Stamataki lab 
that primary hepatocytes phagocytose dead lymphocytes in vivo, providing another 
role conducted by hepatocytes which contribute to homeostasis of the liver. The pro-
inflammatory cytokines IFNγ and IFNγ + TNFα enhanced primary hepatocyte 
phagocytosis (Figure 6C). This was in agreement with data on the regulation of 
phagocytosis in Huh-7 as shown by Weight et al in our lab (unpublished), The 
physiological impact of increased ploidy in hepatocytes, as a result of phagocytosis, 
is uncertain. A mechanism of understanding the significance of these events is to 
outline the situations where phagocytosis would be considerably enhanced. Although 
the number of apoptotic cells in the liver is low, acute liver injury or disease amplifies 
apoptotic-cell death, which induces phagocytic clearing of dead cells by hepatocytes 
(43). It has been suggested that increases in ploidy provide the regenerative 
capacity of hepatocytes (18, 24). As such, polyploidisation following liver injury or 
inflammation may be of benefit, as it may increase the regenerative capacity of the 
liver and promote healing. A second explanation for liver polyploidisation could be 
the promotion of genetic resilience. Previous studies conducted in yeast revealed in 
increasing the number of chromosome sets can mask the acquisition of detrimental 
mutations (6). In addition, the liver is often exposed to mutagenic substances like 
alcohol and drug metabolites (24). As such, phagocytosis by hepatocytes could 
provide protection from harmful mutations through increases in ploidy. Of interest, 
we observed that treatment of primary hepatocytes with cytokines TNFα and IFNγ 
induced a significant increase in the number of cells conducting phagocytosis, as 
well as the number of cells which were internalised by each cell. This suggests that 
these inflammatory cytokines synergistically up-regulate phagocytic responses in 
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hepatocytes. Similar interplay between TNFα and IFNγ have been described in 
macrophage phagocytosis of Listeria monocytogenes and Leishmania major (44, 
45). Hepatocytes may be stimulated through similar mechanisms. As both TNFα and 
IFNγ are secreted by T-cells and natural killer cells (NK) during inflammation, 
cytokine stimulation of hepatocytes may be induced to clear dead material from the 
liver.  
Additionally, it had been previously observed that IFNγ impose an inhibitory effect on 
hepatocyte regeneration (46). Hepatocyte cell division is reduced during 
phagocytosis, which may explain this result.  A further analysis of multinucleation in 
liver sections utilising anti-HNF4α immunohistochemical staining could be conducted 
to elucidate whether ploidy is increased in livers during acute injury or inflammation. 
As spontaneous tumour development is rare in liver, considering that hepatocytes 
are naturally polyploid, it is unlikely that phagocytosis-induced polyploidisation 
promotes tumourigenesis (24, 25). In support of this, we observed that phagocytosis 
did not increase the frequency of cell division in Huh7s (data not shown). This 
evidence implies that hepatocellular carcinoma may not arise from prolong periods of 
phagocytosis, although this should be confirmed using aforementioned IHC analysis 
of cancerous livers. Overall, it is likely that natural increases in liver polyploidy, as a 
result of phagocytosis, are beneficial to overall liver homeostasis, as well as for the 
prevention of and recovery from injury or disease.  
4.3 Phagocytosis may induce cellular differentiation through aneuploidy  
The examination of phagocytosis-induced multinucleation in hepatomas resulted in 
the surprising differentiation of these established cell lines into two separate 
lineages. The molecular processes which underlie this event were not apparent. It is 
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of great interest as to the mechanism of how these differentiated were generated. A 
possibility may be through the generation of aneuploid cells (Figure 10). Karyotyping 
in mouse livers has revealed that 70% of hepatocytes in adults had undergone 
chromosomal loss or gain (13). Further research showed that chromosome from 
each nucleus within tetraploid, binucleate cells are interspersed following 
condensation in metaphase (13). Following this, chromosomes are separated along 
a bipolar or multipolar axis. In this respect, multiple spindle fibres can attach to the 
same kinetochores. These “lagging chromosomes” to not migrate to a specific pole 
and are deleted (14). Daughter cells resulting from this division will have 
chromosomes missing and be genetically distinct to the parent cell. The generation 
of binucleate cells due to phagocytosis could promote aneuploidy in hepatocytes. As 
such the generation of the observed differentiated cell lines could have arisen 
through aneuploidy and the loss of genes which ordinarily would generate the Huh-7 
phenotype. In support of this, differentiation as a result of aneuploidy has been 
observed following long-term culture of mesenchymal stem cells and neuronal cells 
(15, 16). Procedures that were conducted within this investigation could have been 
utilised to examine this possibility; Hoechst staining of DNA could be used to identify 
aneuploidy in Huh-7s throughout cell division once chromosomes have condensed. 
However, as we were observing nuclear alteration in phagocytosing cells, heat-killed 
phagocytosing cells were also stained as by Hoechst. As such, the development of 
aneuploidy within these cells could not be observed. Fluorescence In Situ 
Hybridisation (FISH) analysis of Huh-7s prior to, and following, phagocytosis would 




Differentiated cells underwent minimal cell divisions, a trait which mimics the 
behaviour of ex vivo primary hepatocytes, which normally die following a short time 
in culture.  This quality of primary cells creates difficulties in obtaining accurate 
results when regarding the natural activities of hepatocytes, as they are known to 
regenerate in vivo. However, the differentiated cells were still viable despite not 
undergoing cell division and may represent an accurate and robust model for 
investigating the behaviour of primary hepatocytes. Studies have aspired to achieve 
similar results in hepatoma cell lines through culturing in -media containing dimethyl 
sulfoxide (DMSO), the effects of which have been poorly characterised (17-19). Of 
interest, DMSO treatment has also been shown to induce multinucleation and 
cytokinetic failure in Dictyostelium mucoroides, leading to the generation of giant 
cells (3). Phagocytosis of dead cells may induce differentiation through similar 
mechanisms, although at a lower detriment to cellular physiology and without the 
requirement of further media supplements in order to prevent apoptosis of these 
cells. As such, the techniques described in this investigation could provide a more 
convenient mechanism to obtain data which accurately represents the biology of 








Figure 10: Proposed model for the generation of aneuploid, differentiated cells from Huh7 
phagocytosis. The generation of intracellular vacuole within a hepatocyte, resulting from phagocytosis of a 
dead cell, restricts furrowing during cytokinesis leading to the generation of a tetraploid cell. After the 
phagosome is processed, the tetraploid cell attempts mitosis. Chromosomes from both nuclei intermingle as 
the cell attempts to generate multiple mitotic poles. Bipolar segregation generates “lagging chromosomes” 
which do not migrate to opposites and are subsequently deleted. As such, daughter cells do not receive 
these chromosomes and become aneuploid. Changes in cytoplasm colour depict genotype alterations. 
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4.4 Further Investigation 
4.4.1 Obtaining a molecular understanding of hepatocyte phagocytosis and the 
limitations of heat killing 
Phagocytosis of apoptotic cells is a well-characterised process; the recognition of 
cells presenting phosphatidylserine (PS) on the outer leaflet of the cell membrane by 
phagocytes has been well researched. However, the processes which trigger and 
regulate phagocytosis in hepatocytes are poorly understood. In this investigation we 
set out to determine if phagocytosis of apoptotic cells leads to increased 
multinucleation in hepatomas. We also established the use of ISEL for the specific 
detection of apoptotic cells in vivo. However, we induced phagocytosis in hepatomas 
using cells which had been killed by heat. This strategy was used, mostly for 
convenience, but also to ensure that the phagosome retained its shape containing 
large dead cells (as opposed to the constricting cells that die by apoptosis) and 
creating an intracellular obstruction. As apoptosis results in cellular condensation, 
phagosomes generated from these cells may be smaller and less likely to impose an 
obstacle on cytokinesis. In addition to this, heat-killing is thought to be more 
representative of necrosis, rather than apoptosis. Although a molecular 
understanding of necrotic cell phagocytosis lacking, the mechanisms through which 
it occurs may be distinctly different to that of apoptotic cell engulfment. This brings 
into question the efficacy of heat-killing for accurately representing the 
consequences in hepatocyte multinucleation as a consequence of phagocytosis. 
However, as necrotic death naturally occurs under inflammatory circumstances, it is 
likely that hepatocytes would naturally engulf necrotic cells to maintain liver 
homeostasis (20). Furthermore, it has been shown that both processes, although 
bearing morphological differences, are dependent of PS presentation (21). These 
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data increase our confidence that heat-killed cells can be used to accurately assess 
the impact of phagocytosis on Huh-7 hepatomas as a model of primary hepatocytes.  
4.4.2 Immunohistochemistry can be used to assess the roles of entosis and 
phagocytosis in liver homeostasis 
We developed a technique which combined the use of immunohistochemical staining 
ISEL detection of apoptotic cells. Using this method, both apoptotic cells and CD3+ 
lymphocytes could be visualised within the same liver section. This technique could 
be utilised to analyse the diversity of internalised lymphocytes and determine their 
fate. Individual subtypes of lymphocytes can be identified by the expression of 
exclusive biomarkers. For example, T-reg cells can be isolated based on the 
expression of the transcription factor Foxp3, T-helper 1 cells exclusive express Tbet, 
B-cells are identified by CD19 and CD20 expression, etc (22, 23). Antibodies which 
recognise theses markers can be used to identify individual subsets within tissue 
sections through the use of IHC. Combining these processes with ISEL can also be 
used to determine the fate of each individual subset. As such, we can visualise if 
individual lymphocytes subsets are internalised by hepatocytes. The apoptotic status 
of these cells can also be deduced by simultaneous ISEL treatment. Furthermore, it 
can be distinguished as to whether lymphocytes are internalised through 
phagocytosis or entosis. Benseler et al, eluded that autoreactive CD8+ cells actively 
enter hepatocytes in order to be deleted in a non-apoptotic manner (24). These 
observations could be confirmed using this double staining technique. The 
combination of ISEL and IHC can thus be utilised to decipher the complex 




4.5 Can phagocytosis be manipulated for therapies targeting cancer?  
Hepatocellular carcinoma is the major cancer of human liver cancers and third most 
frequent cause of cancer in the world (26). The development of hepatocellular 
carcinoma is closely linked to hepatitis B/C viral infection and is thought to be 
associated with the dysregulation of genes linked to cell division, growth and 
migration. Surgical intervention is currently the most efficient treatment method of 
hepatocellular carcinoma (27). Evidence from this investigation and others suggests 
that ploidy increases as a result of phagocytosis can minimise the risk of deleterious 
or oncogenic mutations and increase the regenerative capacity of hepatocytes. As 
such, encouraging phagocytosis within the liver may be of therapeutic interest. 
Increased liver generation would improve patients’ chance of survival and the effect 
of recessive oncogenes could be dampened by increasing the number of non-
transformative alleles. In addition, as cells undergo reduced cycles of cell division 
during phagocytosis, encouraging this process could potentially delay the 
progression of hepatocellular carcinoma. Molecular understanding into how 
hepatocytes internalise dead cells is required for such therapies, as it is not plausible 
to increase phagocytosis by promoting cell death within the liver. Understanding how 
Huh-7 cells differentiated as a result of phagocytosis would be of great interest for 
anti-cancer therapies, as these ceased to exhibit characteristics of normal 
hepatomas. As such, increasing the frequency of hepatocyte phagocytosis within the 
liver may provide of mechanism of modulating the progression of hepatocellular 
carcinoma, through increased genetic resilience and differentiation of tumour cells 
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APPENDIX: LIST OF ABBREVIATIONS  
 
Abbreviation Meaning 
ALD Alcoholic liver disease 
AP Alkaline Phosphatase 
BSA Bovine Serum Albumin  
CD Cluster of differentiation 
cdc20 Cell Division Cycle 20 
CMFDA 5-chloromethylfluorescein Diacetate 
DAB Diaminobenzidene 
DAPI 4,6'-diaminide-2-phenylindole  
DMEM Dulbecco’s Modified Eagle Medium 
DNA Deoxyribonucleic acid 
DPX Di-n-butylPhthalate in Xylene. 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EMT Epithelial-Mesenchymal Transition 
FBS Fetal bovine serum 
GFP Green Fluorescent Protein 
GTP Guanosine Triphosphate 
H2B Histone 2B 
HCC Hepatocellular carcinoma 
HEPES 4-(2-hydroxyethyl)-1-piperazineethane sulfonic 
acid 
HNF4α Hepatocyte Nuclear Factor 4α 
HRP Horseraddish peroxidise 
Huh-7 Hepatoma cell line 
IFN Interferon 
IHC Immunohistochemistry  
IMDM Iscove's modified Dulbecco's medium 
ISEL In Situ End Labelling 
LREC Local Research Ethics Commitee 
Mad2 Mitotic Arrest Deficient  
MCF10A 
Cells 
Michigan Cancer Foundation-10A Cells 
MHC Major Histocompatibility Complex 
MLC Myosin Light Chain 
NEAA Non-essential amino acids 
PBC Primary Biliary Cirrohsis  
PBS Phosphate buffer solution 
PFA Paraformaldehyde 
PHH Primary Human Hepatocytes 
PI3K Phosphoinositide 3-kinase 
PI3K Phosphatidylinositol-3-kinase  
PSC Primary Sclerosing Cholangitis  
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RFP Red Fluorescent Protein 
RPMI Roswell Park memorial institute medium 
SFM Serum free medium 
STAT Signal transducer and activator of transcription 
TBS Tris Buffered Saline 
TBS Tris Buffered Saline  
TBST Tris Buffered Saline Tween 
TGF Transforming growth factor 
TNF Tumour necrosis factor 
 
 
